Drugs interactions for Anoro Ellipta ®

  • 298 Major drug interactions (including ingredients like Abametapir, Abatacept, Aclidinium)
  • 679 Moderate drug interactions (including ingredients like Abatacept, Abemaciclib, Abiraterone)
  • 673 Minor drug interactions (including ingredients like Abacavir, Aceclofenac, Acetaminophen)
1650 interactions for Anoro Ellipta ®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Anoro Ellipta ®.
Abametapir
The serum concentration of Vilanterol can be increased when it is combined with Abametapir.
Abatacept
The risk or severity of adverse effects can be increased when Abatacept is combined with Vilanterol.
Aclidinium
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Aclidinium.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Vilanterol.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Vilanterol.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Vilanterol.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vilanterol.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Umeclidinium.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Umeclidinium.
Anakinra
The risk or severity of adverse effects can be increased when Anakinra is combined with Vilanterol.
Anifrolumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Anifrolumab.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Vilanterol is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vilanterol.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Vilanterol.
Aripiprazole
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Umeclidinium.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Umeclidinium.
Avacincaptad pegol
The risk or severity of adverse effects can be increased when Vilanterol is combined with Avacincaptad pegol.
Avacopan
The risk or severity of adverse effects can be increased when Vilanterol is combined with Avacopan.
Azacitidine
The risk or severity of adverse effects can be increased when Azacitidine is combined with Vilanterol.
Azathioprine
The risk or severity of adverse effects can be increased when Azathioprine is combined with Vilanterol.
Bacillus calmette-guerin substrain tice live antigen
The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Vilanterol.
Baricitinib
The risk or severity of adverse effects can be increased when Vilanterol is combined with Baricitinib.
Basiliximab
The risk or severity of adverse effects can be increased when Basiliximab is combined with Vilanterol.
Beclomethasone dipropionate
The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Vilanterol.
Belatacept
The risk or severity of adverse effects can be increased when Belatacept is combined with Vilanterol.
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Vilanterol.
Belinostat
The risk or severity of adverse effects can be increased when Belinostat is combined with Vilanterol.
Belladonna
The risk or severity of adverse effects can be increased when Belladonna is combined with Umeclidinium.
Belumosudil
The risk or severity of adverse effects can be increased when Vilanterol is combined with Belumosudil.
Bendamustine
The risk or severity of adverse effects can be increased when Bendamustine is combined with Vilanterol.
Benzatropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Umeclidinium.
Betamethasone
The risk or severity of adverse effects can be increased when Betamethasone is combined with Vilanterol.
Bexarotene
The risk or severity of adverse effects can be increased when Bexarotene is combined with Vilanterol.
Bimekizumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Bimekizumab.
Bleomycin
The risk or severity of adverse effects can be increased when Bleomycin is combined with Vilanterol.
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Vilanterol.
Bosutinib
The risk or severity of adverse effects can be increased when Bosutinib is combined with Vilanterol.
Brentuximab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Vilanterol.
Brodalumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Brodalumab.
Bromocriptine
Bromocriptine may increase the hypertensive and vasoconstricting activities of Vilanterol.
Brompheniramine
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Umeclidinium.
Budesonide
The risk or severity of adverse effects can be increased when Budesonide is combined with Vilanterol.
Bupropion
The metabolism of Umeclidinium can be decreased when combined with Bupropion.
Busulfan
The risk or severity of adverse effects can be increased when Busulfan is combined with Vilanterol.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vilanterol.
Cabergoline
Cabergoline may increase the hypertensive and vasoconstricting activities of Vilanterol.
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Vilanterol.
Capecitabine
The risk or severity of adverse effects can be increased when Capecitabine is combined with Vilanterol.
Carbamazepine
The risk or severity of adverse effects can be increased when Carbamazepine is combined with Vilanterol.
Carboplatin
The risk or severity of adverse effects can be increased when Carboplatin is combined with Vilanterol.
Carfilzomib
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Vilanterol.
Carmustine
The risk or severity of adverse effects can be increased when Carmustine is combined with Vilanterol.
Certolizumab pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Vilanterol.
Chikungunya vaccine (live, attenuated)
The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Vilanterol.
Chlorambucil
The risk or severity of adverse effects can be increased when Chlorambucil is combined with Vilanterol.
Chloramphenicol
The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Vilanterol.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Umeclidinium.
Ciclesonide
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Vilanterol.
Cinacalcet
The metabolism of Umeclidinium can be decreased when combined with Cinacalcet.
Cisplatin
The risk or severity of adverse effects can be increased when Cisplatin is combined with Vilanterol.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Umeclidinium.
Clobetasol propionate
The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Vilanterol.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Vilanterol.
Clomipramine
The metabolism of Clomipramine can be decreased when combined with Umeclidinium.
Clonidine
The metabolism of Clonidine can be decreased when combined with Umeclidinium.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Umeclidinium.
Cocaine
The risk or severity of adverse effects can be increased when Cocaine is combined with Umeclidinium.
Corticotropin
The risk or severity of adverse effects can be increased when Corticotropin is combined with Vilanterol.
Cortisone acetate
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Vilanterol.
Crovalimab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Crovalimab.
Cyclophosphamide
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Vilanterol.
Cyclosporine
Vilanterol may increase the immunosuppressive activities of Cyclosporine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Umeclidinium.
Cytarabine
The risk or severity of adverse effects can be increased when Cytarabine is combined with Vilanterol.
Dacarbazine
The risk or severity of adverse effects can be increased when Dacarbazine is combined with Vilanterol.
Dacomitinib
The metabolism of Dacomitinib can be decreased when combined with Umeclidinium.
Dactinomycin
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Vilanterol.
Danicopan
The risk or severity of adverse effects can be increased when Vilanterol is combined with Danicopan.
Darifenacin
The risk or severity of adverse effects can be increased when Darifenacin is combined with Umeclidinium.
Daunorubicin
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Vilanterol.
Decitabine
The risk or severity of adverse effects can be increased when Decitabine is combined with Vilanterol.
Deflazacort
The risk or severity of adverse effects can be increased when Vilanterol is combined with Deflazacort.
Desipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Umeclidinium.
Desoximetasone
The risk or severity of adverse effects can be increased when Desoximetasone is combined with Vilanterol.
Deucravacitinib
The risk or severity of adverse effects can be increased when Vilanterol is combined with Deucravacitinib.
Dexamethasone
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Vilanterol.
Dexrazoxane
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vilanterol.
Dicyclomine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Umeclidinium.
Dihydroergocornine
Dihydroergocornine may increase the hypertensive and vasoconstricting activities of Vilanterol.
Dihydroergocristine
Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Vilanterol.
Dihydroergotamine
Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Vilanterol.
Dimethyl fumarate
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Vilanterol.
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Vilanterol.
Diphenhydramine
The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Umeclidinium.
Diroximel fumarate
The risk or severity of adverse effects can be increased when Vilanterol is combined with Diroximel fumarate.
Disopyramide
The risk or severity of adverse effects can be increased when Disopyramide is combined with Umeclidinium.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Vilanterol.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Umeclidinium.
Doxorubicin
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Vilanterol.
Doxylamine
The risk or severity of adverse effects can be increased when Doxylamine is combined with Umeclidinium.
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Vilanterol.
Efgartigimod alfa
The risk or severity of adverse effects can be increased when Vilanterol is combined with Efgartigimod alfa.
Eluxadoline
The risk or severity of constipation can be increased when Umeclidinium is combined with Eluxadoline.
Emapalumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Emapalumab.
Enasidenib
The metabolism of Enasidenib can be decreased when combined with Umeclidinium.
Epirubicin
The risk or severity of adverse effects can be increased when Epirubicin is combined with Vilanterol.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Umeclidinium.
Escitalopram
The risk or severity of adverse effects can be increased when Escitalopram is combined with Umeclidinium.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Vilanterol.
Etoposide
The risk or severity of adverse effects can be increased when Etoposide is combined with Vilanterol.
Everolimus
The risk or severity of adverse effects can be increased when Everolimus is combined with Vilanterol.
Fesoterodine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Umeclidinium.
Flavoxate
The risk or severity of adverse effects can be increased when Flavoxate is combined with Umeclidinium.
Flecainide
The metabolism of Flecainide can be decreased when combined with Umeclidinium.
Floxuridine
The risk or severity of adverse effects can be increased when Floxuridine is combined with Vilanterol.
Flucytosine
The risk or severity of adverse effects can be increased when Flucytosine is combined with Vilanterol.
Fludarabine
The risk or severity of adverse effects can be increased when Fludarabine is combined with Vilanterol.
Fludrocortisone
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Vilanterol.
Flunisolide
The risk or severity of adverse effects can be increased when Flunisolide is combined with Vilanterol.
Fluocinolone acetonide
The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Vilanterol.
Fluocinonide
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Vilanterol.
Fluorometholone
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Vilanterol.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Vilanterol.
Fosphenytoin
The metabolism of Vilanterol can be increased when combined with Fosphenytoin.
Gemcitabine
The risk or severity of adverse effects can be increased when Gemcitabine is combined with Vilanterol.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vilanterol.
Glatiramer
The risk or severity of adverse effects can be increased when Glatiramer is combined with Vilanterol.
Glycerol phenylbutyrate
The metabolism of Umeclidinium can be decreased when combined with Glycerol phenylbutyrate.
Glycopyrronium
The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Umeclidinium.
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Vilanterol.
Guselkumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Guselkumab.
Homatropine methylbromide
The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Umeclidinium.
Human adenovirus e serotype 4 strain cl-68578 antigen
The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Vilanterol.
Hydrocortisone acetate
The risk or severity of adverse effects can be increased when Vilanterol is combined with Hydrocortisone acetate.
Hydrocortisone butyrate
The risk or severity of adverse effects can be increased when Vilanterol is combined with Hydrocortisone butyrate.
Hydrocortisone succinate
The risk or severity of adverse effects can be increased when Vilanterol is combined with Hydrocortisone succinate.
Hydroxyurea
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Vilanterol.
Hydroxyzine
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Hydroxyzine.
Hyoscyamine
The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Umeclidinium.
Ibritumomab tiuxetan
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vilanterol.
Ibrutinib
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Vilanterol.
Idarubicin
The risk or severity of adverse effects can be increased when Idarubicin is combined with Vilanterol.
Idelalisib
The risk or severity of adverse effects can be increased when Idelalisib is combined with Vilanterol.
Ifosfamide
The risk or severity of adverse effects can be increased when Ifosfamide is combined with Vilanterol.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Umeclidinium.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Vilanterol.
Infliximab
The risk or severity of adverse effects can be increased when Infliximab is combined with Vilanterol.
Interferon alfa-2b
The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vilanterol.
Interferon alfa-n3
The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vilanterol.
Interferon beta-1b
The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vilanterol.
Interferon gamma-1b
The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vilanterol.
Ipratropium
The risk or severity of adverse effects can be increased when Ipratropium is combined with Umeclidinium.
Iptacopan
The risk or severity of adverse effects can be increased when Vilanterol is combined with Iptacopan.
Irinotecan
The risk or severity of adverse effects can be increased when Irinotecan is combined with Vilanterol.
Ixabepilone
The risk or severity of adverse effects can be increased when Ixabepilone is combined with Vilanterol.
Ixekizumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Ixekizumab.
Lefamulin
Lefamulin may increase the QTc-prolonging activities of Vilanterol.
Lenalidomide
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Vilanterol.
Lomustine
The risk or severity of adverse effects can be increased when Lomustine is combined with Vilanterol.
Loxapine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Loxapine.
Loxapine
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Loxapine.
Lumacaftor
The metabolism of Vilanterol can be increased when combined with Lumacaftor.
Macimorelin
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Umeclidinium.
Maprotiline
The risk or severity of adverse effects can be increased when Maprotiline is combined with Umeclidinium.
Mechlorethamine
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Vilanterol.
Melphalan
The risk or severity of adverse effects can be increased when Melphalan is combined with Vilanterol.
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Vilanterol.
Mercaptopurine
The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Vilanterol.
Methotrexate
The risk or severity of adverse effects can be increased when Methotrexate is combined with Vilanterol.
Methscopolamine bromide
The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Umeclidinium.
Methylergometrine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Vilanterol.
Methylprednisolone
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Vilanterol.
Mirikizumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Mirikizumab.
Mitomycin
The risk or severity of adverse effects can be increased when Mitomycin is combined with Vilanterol.
Mitotane
The metabolism of Vilanterol can be increased when combined with Mitotane.
Mitoxantrone
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Vilanterol.
Mometasone furoate
The risk or severity of adverse effects can be increased when Vilanterol is combined with Mometasone furoate.
Monomethyl fumarate
The risk or severity of adverse effects can be increased when Vilanterol is combined with Monomethyl fumarate.
Mosunetuzumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Mosunetuzumab.
Mycophenolate mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Vilanterol.
Mycophenolic acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Vilanterol.
Natalizumab
The risk or severity of immunosuppression can be increased when Vilanterol is combined with Natalizumab.
Nelarabine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Vilanterol.
Nicardipine
The risk or severity of adverse effects can be increased when Nicardipine is combined with Umeclidinium.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Umeclidinium.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Vilanterol.
Ocrelizumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Ocrelizumab.
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Vilanterol.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Umeclidinium.
Olaparib
The risk or severity of adverse effects can be increased when Olaparib is combined with Vilanterol.
Orphenadrine
The risk or severity of adverse effects can be increased when Orphenadrine is combined with Umeclidinium.
Oxybutynin
The risk or severity of adverse effects can be increased when Oxybutynin is combined with Umeclidinium.
Ozanimod
The risk or severity of adverse effects can be increased when Vilanterol is combined with Ozanimod.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Vilanterol.
Palbociclib
The risk or severity of adverse effects can be increased when Palbociclib is combined with Vilanterol.
Pancuronium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Umeclidinium.
Paroxetine
The risk or severity of adverse effects can be increased when Paroxetine is combined with Umeclidinium.
Pegaspargase
The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vilanterol.
Pegcetacoplan
The risk or severity of adverse effects can be increased when Vilanterol is combined with Pegcetacoplan.
Peginterferon alfa-2a
The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vilanterol.
Peginterferon alfa-2b
The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vilanterol.
Peginterferon beta-1a
The risk or severity of adverse effects can be increased when Vilanterol is combined with Peginterferon beta-1a.
Pemetrexed
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Vilanterol.
Penicillamine
The risk or severity of adverse effects can be increased when Penicillamine is combined with Vilanterol.
Pentobarbital
The metabolism of Vilanterol can be increased when combined with Pentobarbital.
Pentostatin
The risk or severity of adverse effects can be increased when Pentostatin is combined with Vilanterol.
Pergolide
Pergolide may increase the hypertensive and vasoconstricting activities of Vilanterol.
Phenobarbital
The metabolism of Vilanterol can be increased when combined with Phenobarbital.
Phenylalanine
The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vilanterol.
Phenytoin
The metabolism of Vilanterol can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vilanterol.
Pimozide
The metabolism of Pimozide can be decreased when combined with Umeclidinium.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Vilanterol.
Pirtobrutinib
The risk or severity of adverse effects can be increased when Vilanterol is combined with Pirtobrutinib.
Pomalidomide
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Vilanterol.
Ponatinib
The metabolism of Ponatinib can be decreased when combined with Umeclidinium.
Ponatinib
The risk or severity of adverse effects can be increased when Ponatinib is combined with Vilanterol.
Ponesimod
The risk or severity of bradycardia can be increased when Ponesimod is combined with Vilanterol.
Pozelimab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Pozelimab.
Pralatrexate
The risk or severity of adverse effects can be increased when Pralatrexate is combined with Vilanterol.
Pramlintide
The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Umeclidinium.
Prednisolone
The risk or severity of adverse effects can be increased when Prednisolone is combined with Vilanterol.
Prednisone
The risk or severity of adverse effects can be increased when Prednisone is combined with Vilanterol.
Primidone
The metabolism of Vilanterol can be increased when combined with Primidone.
Procainamide
The metabolism of Procainamide can be decreased when combined with Umeclidinium.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Umeclidinium.
Propafenone
The metabolism of Umeclidinium can be decreased when combined with Propafenone.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Umeclidinium.
Propylthiouracil
The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Vilanterol.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Umeclidinium.
Quinidine
The risk or severity of adverse effects can be increased when Quinidine is combined with Umeclidinium.
Ravulizumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Ravulizumab.
Revefenacin
The risk or severity of adverse effects can be increased when Revefenacin is combined with Umeclidinium.
Rifampin
The metabolism of Vilanterol can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Vilanterol can be increased when combined with Rifapentine.
Rilonacept
The risk or severity of adverse effects can be increased when Rilonacept is combined with Vilanterol.
Risankizumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Risankizumab.
Rituximab
The risk or severity of adverse effects can be increased when Rituximab is combined with Vilanterol.
Rocuronium
The risk or severity of adverse effects can be increased when Rocuronium is combined with Umeclidinium.
Ropeginterferon alfa-2b
The risk or severity of adverse effects can be increased when Vilanterol is combined with Ropeginterferon alfa-2b.
Rozanolixizumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Rozanolixizumab.
Rubella virus vaccine
The risk or severity of infection can be increased when Rubella virus vaccine is combined with Vilanterol.
Ruxolitinib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Vilanterol.
Sarilumab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Sarilumab.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Umeclidinium.
Secretin human
The therapeutic efficacy of Secretin human can be decreased when used in combination with Umeclidinium.
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Vilanterol.
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Vilanterol.
Siponimod
The risk or severity of adverse effects can be increased when Vilanterol is combined with Siponimod.
Sirolimus
The risk or severity of adverse effects can be increased when Sirolimus is combined with Vilanterol.
Smallpox (Vaccinia) Vaccine, Live
The risk or severity of infection can be increased when Smallpox (Vaccinia) Vaccine, Live is combined with Vilanterol.
Solifenacin
The risk or severity of adverse effects can be increased when Solifenacin is combined with Umeclidinium.
Sotalol
The metabolism of Sotalol can be decreased when combined with Umeclidinium.
Spesolimab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Spesolimab.
Streptozocin
The risk or severity of adverse effects can be increased when Streptozocin is combined with Vilanterol.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Vilanterol.
Sutimlimab
The risk or severity of adverse effects can be increased when Vilanterol is combined with Sutimlimab.
Tamoxifen
The metabolism of Tamoxifen can be decreased when combined with Umeclidinium.
Temozolomide
The risk or severity of adverse effects can be increased when Temozolomide is combined with Vilanterol.
Temsirolimus
The risk or severity of adverse effects can be increased when Temsirolimus is combined with Vilanterol.
Teniposide
The risk or severity of adverse effects can be increased when Teniposide is combined with Vilanterol.
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Vilanterol.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Vilanterol.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Vilanterol.
Theophylline
The metabolism of Theophylline can be decreased when combined with Umeclidinium.
Thioridazine
The metabolism of Umeclidinium can be decreased when combined with Thioridazine.
Thiotepa
The risk or severity of adverse effects can be increased when Thiotepa is combined with Vilanterol.
Thonzylamine
The risk or severity of adverse effects can be increased when Thonzylamine is combined with Umeclidinium.
Tioguanine
The risk or severity of adverse effects can be increased when Tioguanine is combined with Vilanterol.
Tiotropium
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Tiotropium.
Tixocortol
The risk or severity of adverse effects can be increased when Vilanterol is combined with Tixocortol.
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Vilanterol.
Tolterodine
The risk or severity of adverse effects can be increased when Tolterodine is combined with Umeclidinium.
Topotecan
The risk or severity of adverse effects can be increased when Topotecan is combined with Vilanterol.
Trabectedin
The metabolism of Trabectedin can be decreased when combined with Umeclidinium.
Trabectedin
The risk or severity of adverse effects can be increased when Trabectedin is combined with Vilanterol.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Umeclidinium.
Trastuzumab emtansine
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Vilanterol.
Trazodone
The risk or severity of QTc prolongation can be increased when Trazodone is combined with Vilanterol.
Tretinoin
The risk or severity of elevated intracranial pressure can be increased when Vilanterol is combined with Tretinoin.
Triamcinolone
The risk or severity of adverse effects can be increased when Triamcinolone is combined with Vilanterol.
Trifluridine
The risk or severity of adverse effects can be increased when Trifluridine is combined with Vilanterol.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Umeclidinium.
Trimipramine
The metabolism of Trimipramine can be decreased when combined with Umeclidinium.
Trospium
The risk or severity of adverse effects can be increased when Trospium is combined with Umeclidinium.
Typhoid Vaccine Live
The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Vilanterol.
Upadacitinib
The risk or severity of adverse effects can be increased when Vilanterol is combined with Upadacitinib.
Varicella zoster vaccine (live/attenuated)
The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Vilanterol.
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Vilanterol.
Vinblastine
The risk or severity of adverse effects can be increased when Vinblastine is combined with Vilanterol.
Vincristine
The risk or severity of adverse effects can be increased when Vincristine is combined with Vilanterol.
Vinorelbine
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Vilanterol.
Voclosporin
The risk or severity of adverse effects can be increased when Vilanterol is combined with Voclosporin.
Yellow fever vaccine
The risk or severity of infection can be increased when Yellow fever vaccine is combined with Vilanterol.
Zidovudine
The risk or severity of adverse effects can be increased when Zidovudine is combined with Vilanterol.
Zilucoplan
The risk or severity of adverse effects can be increased when Vilanterol is combined with Zilucoplan.
Ziprasidone
The risk or severity of adverse effects can be increased when Ziprasidone is combined with Umeclidinium.
Ziprasidone
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Ziprasidone.
Abatacept
The metabolism of Umeclidinium can be increased when combined with Abatacept.
Abemaciclib
The serum concentration of Abemaciclib can be increased when it is combined with Umeclidinium.
Abiraterone
The metabolism of Umeclidinium can be decreased when combined with Abiraterone.
Abrocitinib
The serum concentration of Umeclidinium can be increased when it is combined with Abrocitinib.
Acebutolol
The metabolism of Umeclidinium can be decreased when combined with Acebutolol.
Acebutolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Acebutolol.
Acrivastine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Acrivastine.
Adagrasib
The serum concentration of Umeclidinium can be increased when it is combined with Adagrasib.
Adagrasib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Adagrasib.
Adalimumab
The metabolism of Umeclidinium can be increased when combined with Adalimumab.
Adenosine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Adenosine.
Afatinib
The serum concentration of Umeclidinium can be increased when it is combined with Afatinib.
Albuterol
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Salbutamol.
Alcaftadine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Alcaftadine.
Alfentanil
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Alfentanil.
Alfuzosin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Alfuzosin.
Amantadine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Amantadine.
Ambrisentan
The serum concentration of Umeclidinium can be increased when it is combined with Ambrisentan.
Amifampridine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Amifampridine.
Amikacin
Vilanterol may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiodarone
The serum concentration of Umeclidinium can be increased when it is combined with Amiodarone.
Amiodarone
The serum concentration of Vilanterol can be increased when it is combined with Amiodarone.
Amisulpride
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Amisulpride.
Amitriptyline
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Amitriptyline.
Amoxapine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Amoxapine.
Anagrelide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Anagrelide.
Anakinra
The metabolism of Umeclidinium can be increased when combined with Anakinra.
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Vilanterol.
Apalutamide
The serum concentration of Umeclidinium can be decreased when it is combined with Apalutamide.
Apalutamide
The serum concentration of Vilanterol can be decreased when it is combined with Apalutamide.
Apixaban
The serum concentration of Umeclidinium can be increased when it is combined with Apixaban.
Apomorphine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Apomorphine.
Apremilast
The metabolism of Umeclidinium can be increased when combined with Apremilast.
Aprepitant
The metabolism of Vilanterol can be decreased when combined with Aprepitant.
Arformoterol
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Arformoterol.
Aripiprazole
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Aripiprazole.
Aripiprazole lauroxil
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Aripiprazole lauroxil.
Arsenic trioxide
The serum concentration of Umeclidinium can be increased when it is combined with Arsenic trioxide.
Arsenic trioxide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Arsenic trioxide.
Artemether
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Artemether.
Asciminib
The serum concentration of Umeclidinium can be increased when it is combined with Asciminib.
Asenapine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Asenapine.
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Vilanterol.
Asunaprevir
The metabolism of Umeclidinium can be decreased when combined with Asunaprevir.
Atazanavir
The serum concentration of Vilanterol can be increased when it is combined with Atazanavir.
Atenolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Atenolol.
Atomoxetine
Atomoxetine may increase the tachycardic activities of Vilanterol.
Atropine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Atropine.
Avanafil
The serum concentration of Umeclidinium can be increased when it is combined with Avanafil.
Avanafil
The serum concentration of Avanafil can be increased when it is combined with Vilanterol.
Axitinib
The serum concentration of Axitinib can be increased when it is combined with Umeclidinium.
Azithromycin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Azithromycin.
Bedaquiline
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Bedaquiline.
Belinostat
The serum concentration of Umeclidinium can be increased when it is combined with Belinostat.
Belumosudil
The serum concentration of Umeclidinium can be increased when it is combined with Belumosudil.
Bendamustine
The serum concentration of Bendamustine can be increased when it is combined with Umeclidinium.
Bendroflumethiazide
The risk or severity of hypokalemia can be increased when Bendroflumethiazide is combined with Vilanterol.
Benzatropine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Benzatropine.
Benzhydrocodone
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Benzhydrocodone.
Benzylpenicilloyl polylysine
Vilanterol may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Berotralstat
The metabolism of Umeclidinium can be decreased when combined with Berotralstat.
Berotralstat
The metabolism of Vilanterol can be decreased when combined with Berotralstat.
Besifloxacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Besifloxacin.
Betaxolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Betaxolol.
Betrixaban
The serum concentration of Betrixaban can be increased when it is combined with Umeclidinium.
Bimekizumab
The metabolism of Umeclidinium can be increased when combined with Bimekizumab.
Binimetinib
The serum concentration of Binimetinib can be increased when it is combined with Umeclidinium.
Bisoprolol
The serum concentration of Umeclidinium can be increased when it is combined with Bisoprolol.
Bisoprolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Bisoprolol.
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Vilanterol.
Bortezomib
The serum concentration of Bortezomib can be increased when it is combined with Umeclidinium.
Bortezomib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Bortezomib.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Umeclidinium.
Botulinum toxin type B
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Botulinum toxin type B.
Brentuximab vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Umeclidinium.
Bretylium
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Bretylium.
Brexpiprazole
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Brexpiprazole.
Brompheniramine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Brompheniramine.
Bumetanide
The risk or severity of hypokalemia can be increased when Bumetanide is combined with Vilanterol.
Buprenorphine
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Buprenorphine.
Butorphanol
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Butorphanol.
Cabergoline
The serum concentration of Cabergoline can be increased when it is combined with Umeclidinium.
Canagliflozin
The serum concentration of Umeclidinium can be increased when it is combined with Canagliflozin.
Canakinumab
The metabolism of Umeclidinium can be increased when combined with Canakinumab.
Cannabidiol
The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with Cannabidiol.
Capmatinib
The serum concentration of Umeclidinium can be increased when it is combined with Capmatinib.
Capreomycin
Vilanterol may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Carbinoxamine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Carbinoxamine.
Carfilzomib
The serum concentration of Umeclidinium can be increased when it is combined with Carfilzomib.
Carteolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Carteolol.
Carvedilol
The serum concentration of Umeclidinium can be increased when it is combined with Carvedilol.
Carvedilol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Carvedilol.
Celecoxib
The metabolism of Umeclidinium can be decreased when combined with Celecoxib.
Cenobamate
The serum concentration of Vilanterol can be decreased when it is combined with Cenobamate.
Ceritinib
The serum concentration of Ceritinib can be increased when it is combined with Umeclidinium.
Ceritinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Ceritinib.
Certolizumab pegol
The metabolism of Umeclidinium can be increased when combined with Certolizumab pegol.
Cetirizine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Cetirizine.
Chlorcyclizine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Chlorcyclizine.
Chloroquine
The metabolism of Umeclidinium can be decreased when combined with Chloroquine.
Chloroquine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Chloroquine.
Chlorothiazide
The risk or severity of hypokalemia can be increased when Chlorothiazide is combined with Vilanterol.
Chlorpheniramine
The metabolism of Umeclidinium can be decreased when combined with Chlorpheniramine.
Chlorpheniramine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Chlorpheniramine.
Chlorpromazine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Chlorpromazine.
Cholecalciferol
The metabolism of Umeclidinium can be decreased when combined with Cholecalciferol.
Cilostazol
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Cilostazol.
Ciprofloxacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Ciprofloxacin.
Citalopram
The metabolism of Umeclidinium can be decreased when combined with Citalopram.
Citalopram
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Citalopram.
Clarithromycin
The serum concentration of Umeclidinium can be increased when it is combined with Clarithromycin.
Clarithromycin
The serum concentration of Vilanterol can be increased when it is combined with Clarithromycin.
Clemastine
The metabolism of Umeclidinium can be decreased when combined with Clemastine.
Clemastine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Clemastine.
Clobazam
The serum concentration of Umeclidinium can be increased when it is combined with Clobazam.
Clomifene
The serum concentration of Umeclidinium can be increased when it is combined with Clomifene.
Clomipramine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Clomipramine.
Clostridium tetani toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vilanterol.
Clozapine
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Clozapine.
Cobicistat
The serum concentration of Umeclidinium can be increased when it is combined with Cobicistat.
Cobimetinib
The serum concentration of Cobimetinib can be increased when it is combined with Umeclidinium.
Cocaine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Codeine.
Colchicine
The serum concentration of Umeclidinium can be increased when it is combined with Colchicine.
Colistin
Vilanterol may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan
The serum concentration of Umeclidinium can be increased when it is combined with Conivaptan.
Conivaptan
The serum concentration of Vilanterol can be increased when it is combined with Conivaptan.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vilanterol.
Crizotinib
The serum concentration of Umeclidinium can be increased when it is combined with Crizotinib.
Crizotinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Crizotinib.
Curcumin
The metabolism of Umeclidinium can be decreased when combined with Curcumin.
Curcumin
The serum concentration of Vilanterol can be increased when it is combined with Curcumin.
Cyclosporine
The metabolism of Umeclidinium can be decreased when combined with Cyclosporine.
Cyproheptadine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Cyproheptadine.
Dabigatran etexilate
The serum concentration of Umeclidinium can be increased when it is combined with Dabigatran etexilate.
Dabrafenib
The serum concentration of Dabrafenib can be increased when it is combined with Umeclidinium.
Dabrafenib
The serum concentration of Vilanterol can be decreased when it is combined with Dabrafenib.
Dactinomycin
The serum concentration of Dactinomycin can be increased when it is combined with Umeclidinium.
Danazol
The serum concentration of Vilanterol can be increased when it is combined with Danazol.
Danicopan
The serum concentration of Umeclidinium can be increased when it is combined with Danicopan.
Daptomycin
The serum concentration of Umeclidinium can be increased when it is combined with Daptomycin.
Darolutamide
The serum concentration of Darolutamide can be increased when it is combined with Umeclidinium.
Darunavir
The metabolism of Umeclidinium can be decreased when combined with Darunavir.
Darunavir
The serum concentration of Vilanterol can be increased when it is combined with Darunavir.
Dasabuvir
The serum concentration of Dasabuvir can be increased when it is combined with Umeclidinium.
Dasatinib
The serum concentration of Dasatinib can be increased when it is combined with Umeclidinium.
Dasatinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Dasatinib.
Degarelix
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Degarelix.
Delafloxacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Delafloxacin.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Vilanterol.
Desflurane
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Desflurane.
Desipramine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Desipramine.
Desloratadine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Desloratadine.
Desvenlafaxine
Desvenlafaxine may increase the tachycardic activities of Vilanterol.
Deutetrabenazine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Deutetrabenazine.
Deutivacaftor
The serum concentration of Umeclidinium can be increased when it is combined with Deutivacaftor.
Dexamethasone acetate
The risk or severity of hypokalemia can be increased when Dexamethasone acetate is combined with Vilanterol.
Dexbrompheniramine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Dexbrompheniramine.
Dexchlorpheniramine maleate
The metabolism of Umeclidinium can be decreased when combined with Dexchlorpheniramine maleate.
Dexchlorpheniramine maleate
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Dexchlorpheniramine maleate.
Dexmedetomidine
The metabolism of Umeclidinium can be decreased when combined with Dexmedetomidine.
Dextropropoxyphene
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Dextropropoxyphene.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Umeclidinium.
Digoxin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Digoxin.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Dihydrocodeine.
Diltiazem
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Diltiazem.
Dimenhydrinate
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Dimenhydrinate.
Dimethyl sulfoxide
The metabolism of Umeclidinium can be decreased when combined with Dimethyl sulfoxide.
Diosmin
The serum concentration of Umeclidinium can be increased when it is combined with Diosmin.
Diphenhydramine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Diphenhydramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Diphenoxylate.
Disopyramide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Disopyramide.
Disulfiram
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Disulfiram.
Dobutamine
The risk or severity of adverse effects can be increased when Dobutamine is combined with Vilanterol.
Dofetilide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Dofetilide.
Dolasetron
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Dolasetron.
Dolutegravir
The serum concentration of Umeclidinium can be increased when it is combined with Dolutegravir.
Donepezil
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Donepezil.
Doxazosin
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Doxazosin.
Doxepin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Doxepin.
Doxorubicin
The metabolism of Umeclidinium can be decreased when combined with Doxorubicin.
Doxylamine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Doxylamine.
Dronabinol
The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with Dronabinol.
Dronedarone
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Dronedarone.
Droperidol
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Droperidol.
Droxidopa
The risk or severity of adverse effects can be increased when Droxidopa is combined with Vilanterol.
Duloxetine
The metabolism of Umeclidinium can be decreased when combined with Duloxetine.
Duloxetine
Duloxetine may increase the tachycardic activities of Vilanterol.
Duvelisib
The serum concentration of Duvelisib can be increased when it is combined with Umeclidinium.
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Vilanterol.
Echothiophate
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Echothiophate.
Econazole
The serum concentration of Vilanterol can be increased when it is combined with Econazole.
Edoxaban
The serum concentration of Umeclidinium can be increased when it is combined with Edoxaban.
Efavirenz
The serum concentration of Vilanterol can be increased when it is combined with Efavirenz.
Elacestrant
The serum concentration of Umeclidinium can be increased when it is combined with Elacestrant.
Elagolix
The serum concentration of Umeclidinium can be increased when it is combined with Elagolix.
Elasomeran
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Vilanterol.
Elbasvir
The serum concentration of Elbasvir can be increased when it is combined with Umeclidinium.
Eliglustat
The metabolism of Umeclidinium can be decreased when combined with Eliglustat.
Eliglustat
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Eliglustat.
Elvitegravir
The serum concentration of Vilanterol can be increased when it is combined with Elvitegravir.
Emapalumab
The metabolism of Umeclidinium can be increased when combined with Emapalumab.
Emedastine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Emedastine.
Encorafenib
The serum concentration of Umeclidinium can be increased when it is combined with Encorafenib.
Encorafenib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Encorafenib.
Enfortumab vedotin
The serum concentration of Enfortumab vedotin can be increased when it is combined with Umeclidinium.
Entrectinib
The serum concentration of Umeclidinium can be increased when it is combined with Entrectinib.
Entrectinib
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Entrectinib.
Enzalutamide
The serum concentration of Vilanterol can be decreased when it is combined with Enzalutamide.
Epcoritamab
The serum concentration of Vilanterol can be increased when it is combined with Epcoritamab.
Epinastine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Epinastine.
Epinephrine
The risk or severity of adverse effects can be increased when Epinephrine is combined with Vilanterol.
Erdafitinib
The serum concentration of Umeclidinium can be increased when it is combined with Erdafitinib.
Ergotamine
The serum concentration of Vilanterol can be increased when it is combined with Ergotamine.
Eribulin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Eribulin.
Erlotinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Erlotinib.
Erythromycin
The serum concentration of Umeclidinium can be increased when it is combined with Erythromycin.
Erythromycin
The serum concentration of Vilanterol can be increased when it is combined with Erythromycin.
Escitalopram
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Escitalopram.
Esketamine
The risk or severity of hypertension can be increased when Esketamine is combined with Vilanterol.
Esmolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Esmolol.
Etacrynic acid
The risk or severity of hypokalemia can be increased when Etacrynic acid is combined with Vilanterol.
Etanercept
The metabolism of Umeclidinium can be increased when combined with Etanercept.
Ethosuximide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Ethosuximide.
Etoposide
The serum concentration of Etoposide can be increased when it is combined with Umeclidinium.
Etrasimod
The risk or severity of QTc prolongation and torsade de pointes can be increased when Etrasimod is combined with Vilanterol.
Everolimus
The serum concentration of Umeclidinium can be increased when it is combined with Everolimus.
Famotidine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Famotidine.
Fedratinib
The serum concentration of Umeclidinium can be increased when it is combined with Fedratinib.
Fedratinib
The serum concentration of Vilanterol can be increased when it is combined with Fedratinib.
Felbamate
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Felbamate.
Felodipine
The metabolism of Umeclidinium can be decreased when combined with Felodipine.
Felodipine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Felodipine.
Fenfluramine
The metabolism of Umeclidinium can be decreased when combined with Fenfluramine.
Fentanyl
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Fentanyl.
Fexinidazole
The risk or severity of adverse effects can be increased when Vilanterol is combined with Fexinidazole.
Fexofenadine
The serum concentration of Umeclidinium can be increased when it is combined with Fexofenadine.
Fingolimod
Vilanterol may increase the immunosuppressive activities of Fingolimod.
Flecainide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Flecainide.
Flibanserin
The serum concentration of Umeclidinium can be increased when it is combined with Flibanserin.
Fluconazole
The serum concentration of Umeclidinium can be increased when it is combined with Fluconazole.
Fluconazole
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Fluconazole.
Fluorouracil
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Fluorouracil.
Fluoxetine
The serum concentration of Umeclidinium can be increased when it is combined with Fluoxetine.
Fluoxetine
The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Vilanterol.
Fluvoxamine
The metabolism of Umeclidinium can be decreased when combined with Fluvoxamine.
Fluvoxamine
The metabolism of Vilanterol can be decreased when combined with Fluvoxamine.
Formoterol
Vilanterol may increase the sympathomimetic activities of Formoterol.
Foscarnet
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Foscarnet.
Fosnetupitant
The metabolism of Vilanterol can be decreased when combined with Fosnetupitant.
Fostemsavir
The serum concentration of Fostemsavir can be increased when it is combined with Umeclidinium.
Furosemide
The risk or severity of hypokalemia can be increased when Furosemide is combined with Vilanterol.
Fusidic acid
The metabolism of Umeclidinium can be decreased when combined with Fusidic acid.
Fusidic acid
The metabolism of Vilanterol can be decreased when combined with Fusidic acid.
Futibatinib
The serum concentration of Futibatinib can be increased when it is combined with Umeclidinium.
Gadobenic acid
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Gadobenic acid.
Galantamine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Galantamine.
Gatifloxacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Gatifloxacin.
Gemcitabine
The serum concentration of Gemcitabine can be increased when it is combined with Umeclidinium.
Gemifloxacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Gemifloxacin.
Gentamicin
Vilanterol may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gepirone
The risk or severity of QTc prolongation can be increased when Gepirone is combined with Vilanterol.
Gepotidacin
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Gepotidacin.
Gepotidacin
The risk or severity of QTc prolongation can be increased when Gepotidacin is combined with Vilanterol.
Gilteritinib
The serum concentration of Gilteritinib can be increased when it is combined with Umeclidinium.
Gilteritinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Gilteritinib.
Givinostat
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Givinostat.
Givosiran
The serum concentration of Umeclidinium can be increased when it is combined with Givosiran.
Glasdegib
The serum concentration of Umeclidinium can be increased when it is combined with Glasdegib.
Glasdegib
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Glasdegib.
Glecaprevir
The serum concentration of Umeclidinium can be increased when it is combined with Glecaprevir.
Glofitamab
The serum concentration of Vilanterol can be increased when it is combined with Glofitamab.
Glucagon
Umeclidinium may increase the gastrointestinal motility reducing activities of Glucagon.
Golimumab
The metabolism of Umeclidinium can be increased when combined with Golimumab.
Goserelin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Goserelin.
Granisetron
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Granisetron.
Grazoprevir
The serum concentration of Grazoprevir can be increased when it is combined with Umeclidinium.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Vilanterol.
Haloperidol
The serum concentration of Umeclidinium can be increased when it is combined with Haloperidol.
Haloperidol
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Haloperidol.
Hepatitis A Vaccine
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vilanterol.
Hepatitis B Vaccine (Recombinant)
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Vilanterol.
Histrelin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Histrelin.
Hydrochlorothiazide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Hydrochlorothiazide.
Hydrocodone
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Hydrocodone.
Hydrocortisone
The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Vilanterol.
Hydroflumethiazide
The risk or severity of hypokalemia can be increased when Hydroflumethiazide is combined with Vilanterol.
Hydromorphone
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Hydromorphone.
Hydroxychloroquine
The metabolism of Umeclidinium can be decreased when combined with Hydroxychloroquine.
Hydroxychloroquine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Hydroxychloroquine.
Hydroxyzine
The metabolism of Umeclidinium can be decreased when combined with Hydroxyzine.
Hyoscyamine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Hyoscyamine.
Ibandronate
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Ibandronate.
Ibutilide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Ibutilide.
Idelalisib
The serum concentration of Umeclidinium can be increased when it is combined with Idelalisib.
Iloperidone
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Iloperidone.
Imatinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Imatinib.
Imipramine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Imipramine.
Indapamide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Indapamide.
Indinavir
The serum concentration of Vilanterol can be increased when it is combined with Indinavir.
Infliximab
The metabolism of Umeclidinium can be increased when combined with Infliximab.
Inotersen
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Inotersen.
Inotuzumab ozogamicin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Inotuzumab ozogamicin.
Isavuconazonium
The serum concentration of Umeclidinium can be increased when it is combined with Isavuconazonium.
Isavuconazonium
The metabolism of Vilanterol can be decreased when combined with Isavuconazonium.
Isocarboxazid
The risk or severity of hypertension and cardiovascular complications can be increased when Isocarboxazid is combined with Vilanterol.
Isoflurane
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Isoflurane.
Isoniazid
The metabolism of Vilanterol can be decreased when combined with Isoniazid.
Isoprenaline
The risk or severity of adverse effects can be increased when Isoprenaline is combined with Vilanterol.
Isradipine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Isradipine.
Istradefylline
The serum concentration of Umeclidinium can be increased when it is combined with Istradefylline.
Itraconazole
The serum concentration of Umeclidinium can be increased when it is combined with Itraconazole.
Itraconazole
The serum concentration of Vilanterol can be increased when it is combined with Itraconazole.
Ivabradine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Ivabradine.
Ivacaftor
The serum concentration of Umeclidinium can be increased when it is combined with Ivacaftor.
Ivacaftor
The serum concentration of Vilanterol can be increased when it is combined with Ivacaftor.
Ivosidenib
The metabolism of Vilanterol can be increased when combined with Ivosidenib.
Ixabepilone
The serum concentration of Umeclidinium can be increased when it is combined with Ixabepilone.
Janssen COVID-19 Vaccine
The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Vilanterol.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Vilanterol.
Ketoconazole
The metabolism of Umeclidinium can be decreased when combined with Ketoconazole.
Ketoconazole
The serum concentration of Vilanterol can be increased when it is combined with Ketoconazole.
Labetalol
The metabolism of Umeclidinium can be decreased when combined with Labetalol.
Labetalol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Labetalol.
Lamotrigine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Lamotrigine.
Landiolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Landiolol.
Lapatinib
The serum concentration of Umeclidinium can be increased when it is combined with Lapatinib.
Lapatinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Lapatinib.
Lasmiditan
The serum concentration of Umeclidinium can be increased when it is combined with Lasmiditan.
Ledipasvir
The serum concentration of Umeclidinium can be increased when it is combined with Ledipasvir.
Lefamulin
The serum concentration of Lefamulin can be increased when it is combined with Umeclidinium.
Leflunomide
The risk or severity of adverse effects can be increased when Vilanterol is combined with Leflunomide.
Lemborexant
The serum concentration of Lemborexant can be increased when it is combined with Umeclidinium.
Lenacapavir
The serum concentration of Lenacapavir can be increased when it is combined with Umeclidinium.
Lenvatinib
The serum concentration of Lenvatinib can be increased when it is combined with Umeclidinium.
Lenvatinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Lenvatinib.
Leuprolide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Leuprolide.
Levobunolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Levobunolol.
Levocabastine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Levocabastine.
Levocetirizine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Levocetirizine.
Levodopa
The absorption of Levodopa can be decreased when combined with Umeclidinium.
Levofloxacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Levofloxacin.
Levoketoconazole
The serum concentration of Umeclidinium can be increased when it is combined with Levoketoconazole.
Levoketoconazole
The serum concentration of Vilanterol can be increased when it is combined with Levoketoconazole.
Levomilnacipran
Levomilnacipran may increase the tachycardic activities of Vilanterol.
Levorphanol
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Levorphanol.
Levosalbutamol
The risk or severity of adverse effects can be increased when Vilanterol is combined with Levosalbutamol.
Lidocaine
The metabolism of Umeclidinium can be decreased when combined with Lidocaine.
Linagliptin
The serum concentration of Umeclidinium can be increased when it is combined with Linagliptin.
Linagliptin
The metabolism of Vilanterol can be decreased when combined with Linagliptin.
Linezolid
The risk or severity of hypertension and cardiovascular complications can be increased when Linezolid is combined with Vilanterol.
Lithium carbonate
Vilanterol may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lofexidine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Lofexidine.
Lomefloxacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Lomefloxacin.
Lomitapide
The serum concentration of Umeclidinium can be increased when it is combined with Lomitapide.
Lonafarnib
The serum concentration of Umeclidinium can be increased when it is combined with Lonafarnib.
Lonafarnib
The serum concentration of Vilanterol can be increased when it is combined with Lonafarnib.
Loncastuximab tesirine
The serum concentration of Loncastuximab tesirine can be increased when it is combined with Umeclidinium.
Loperamide
The serum concentration of Umeclidinium can be increased when it is combined with Loperamide.
Loperamide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Loperamide.
Lopinavir
The serum concentration of Umeclidinium can be increased when it is combined with Lopinavir.
Lopinavir
The serum concentration of Vilanterol can be increased when it is combined with Lopinavir.
Lumacaftor
The serum concentration of Umeclidinium can be decreased when it is combined with Lumacaftor.
Lumefantrine
The metabolism of Umeclidinium can be decreased when combined with Lumefantrine.
Lumefantrine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Lumefantrine.
Lurasidone
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Lurasidone.
Lusutrombopag
The serum concentration of Lusutrombopag can be increased when it is combined with Umeclidinium.
Macimorelin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Macimorelin.
Magnesium
The serum concentration of Magnesium can be decreased when it is combined with Vilanterol.
Malathion
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Malathion.
Mannitol
The serum concentration of Umeclidinium can be increased when it is combined with Mannitol.
Maprotiline
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Maprotiline.
Maribavir
The serum concentration of Umeclidinium can be increased when it is combined with Maribavir.
Mavacamten
The serum concentration of Vilanterol can be decreased when it is combined with Mavacamten.
Mavorixafor
The serum concentration of Umeclidinium can be increased when it is combined with Mavorixafor.
Measles virus vaccine live attenuated
The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Vilanterol.
Mefloquine
The serum concentration of Umeclidinium can be increased when it is combined with Mefloquine.
Mefloquine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Mefloquine.
Meperidine
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Meperidine.
Mepyramine
The metabolism of Umeclidinium can be decreased when combined with Mepyramine.
Mepyramine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Mepyramine.
Methacholine
Umeclidinium may decrease effectiveness of Methacholine as a diagnostic agent.
Methacholine
Vilanterol may decrease effectiveness of Methacholine as a diagnostic agent.
Methadone
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Methadone.
Methadone
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Methadone.
Methimazole
The metabolism of Umeclidinium can be decreased when combined with Methimazole.
Methimazole
The serum concentration of Vilanterol can be increased when it is combined with Methimazole.
Methsuximide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Methsuximide.
Methylene blue
The serum concentration of Umeclidinium can be increased when it is combined with Methylene blue.
Methylene blue
The risk or severity of hypertension and cardiovascular complications can be increased when Methylene blue is combined with Vilanterol.
Methylprednisolone hemisuccinate
The risk or severity of hypokalemia can be increased when Methylprednisolone hemisuccinate is combined with Vilanterol.
Metoclopramide
The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Umeclidinium.
Metoclopramide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Metoclopramide.
Metoprolol
The metabolism of Umeclidinium can be decreased when combined with Metoprolol.
Metoprolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Metoprolol.
Metronidazole
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Metronidazole.
Miconazole
The metabolism of Umeclidinium can be decreased when combined with Miconazole.
Miconazole
The metabolism of Vilanterol can be decreased when combined with Miconazole.
Midazolam
The serum concentration of Umeclidinium can be increased when it is combined with Midazolam.
Midostaurin
The serum concentration of Vilanterol can be increased when it is combined with Midostaurin.
Mifepristone
The serum concentration of Umeclidinium can be increased when it is combined with Mifepristone.
Mifepristone
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Mifepristone.
Milnacipran
Milnacipran may increase the tachycardic activities of Vilanterol.
Mirabegron
The risk or severity of urinary retention can be increased when Umeclidinium is combined with Mirabegron.
Mirabegron
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Mirabegron.
Mirtazapine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Mirtazapine.
Mitapivat
The serum concentration of Umeclidinium can be increased when it is combined with Mitapivat.
Modified vaccinia ankara
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Vilanterol.
Moexipril
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Moexipril.
Morphine
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Morphine.
Moxifloxacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Moxifloxacin.
mRNA-1345
The therapeutic efficacy of mRNA-1345 can be decreased when used in combination with Vilanterol.
Mumps virus strain B level jeryl lynn live antigen
The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Vilanterol.
Nabilone
The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with Nabilone.
Nadolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Nadolol.
Nalbuphine
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Nalbuphine.
Naloxegol
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Naloxegol.
Naltrexone
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Naltrexone.
Nebivolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Nebivolol.
Nefazodone
The serum concentration of Vilanterol can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Vilanterol can be increased when it is combined with Nelfinavir.
Neomycin
Vilanterol may decrease the excretion rate of Neomycin which could result in a higher serum level.
Neratinib
The serum concentration of Umeclidinium can be increased when it is combined with Neratinib.
Netupitant
The serum concentration of Umeclidinium can be increased when it is combined with Netupitant.
Netupitant
The metabolism of Vilanterol can be decreased when combined with Netupitant.
Niacin
The metabolism of Umeclidinium can be decreased when combined with Niacin.
Nicardipine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Nicardipine.
Nifedipine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Nifedipine.
Nilotinib
The serum concentration of Umeclidinium can be increased when it is combined with Nilotinib.
Nilotinib
The serum concentration of Vilanterol can be increased when it is combined with Nilotinib.
Nimodipine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Nimodipine.
Nintedanib
The serum concentration of Nintedanib can be increased when it is combined with Umeclidinium.
Nirogacestat
The serum concentration of Umeclidinium can be increased when it is combined with Nirogacestat.
Norepinephrine
The risk or severity of adverse effects can be increased when Norepinephrine is combined with Vilanterol.
Norgestimate
The serum concentration of Umeclidinium can be increased when it is combined with Norgestimate.
Nortriptyline
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Nortriptyline.
Nuvaxovid
The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Vilanterol.
Octreotide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Octreotide.
Ofloxacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Ofloxacin.
Olanzapine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Olanzapine.
Oliceridine
The risk or severity of urinary retention, reduced gastrointestinal motility, and constipation can be increased when Umeclidinium is combined with Oliceridine.
Olodaterol
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Olodaterol.
Omadacycline
The serum concentration of Omadacycline can be increased when it is combined with Umeclidinium.
Ombitasvir
The serum concentration of Ombitasvir can be increased when it is combined with Umeclidinium.
Ondansetron
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Ondansetron.
Opium
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Opium.
Orciprenaline
The risk or severity of adverse effects can be increased when Orciprenaline is combined with Vilanterol.
Orphenadrine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Orphenadrine.
Osimertinib
The serum concentration of Osimertinib can be increased when it is combined with Umeclidinium.
Oxaliplatin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Oxaliplatin.
Oxycodone
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Oxycodone.
Oxymorphone
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Oxymorphone.
Oxytocin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Oxytocin.
Pacritinib
The serum concentration of Umeclidinium can be increased when it is combined with Pacritinib.
Pacritinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Pacritinib.
Palbociclib
The serum concentration of Umeclidinium can be increased when it is combined with Palbociclib.
Paliperidone
The serum concentration of Umeclidinium can be increased when it is combined with Paliperidone.
Paliperidone
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Paliperidone.
Panobinostat
The metabolism of Umeclidinium can be decreased when combined with Panobinostat.
Panobinostat
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Panobinostat.
Papaverine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Papaverine.
Paritaprevir
The serum concentration of Paritaprevir can be increased when it is combined with Umeclidinium.
Pasireotide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Pasireotide.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Umeclidinium.
Pazopanib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Pazopanib.
Pentamidine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Pentamidine.
Pentazocine
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Pentazocine.
Perflutren
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Perflutren.
Perphenazine
The metabolism of Umeclidinium can be decreased when combined with Perphenazine.
Phenelzine
The risk or severity of hypertension and cardiovascular complications can be increased when Phenelzine is combined with Vilanterol.
Pheniramine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Pheniramine.
Phenoxybenzamine
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Phenoxybenzamine.
Phentolamine
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Phentolamine.
Phenylbutyric acid
The metabolism of Umeclidinium can be decreased when combined with Phenylbutyric acid.
Pibrentasvir
The serum concentration of Umeclidinium can be increased when it is combined with Pibrentasvir.
Pimavanserin
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Pimavanserin.
Pimozide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Pimozide.
Pinaverium
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Pinaverium.
Pindolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Pindolol.
Piperine
The serum concentration of Umeclidinium can be increased when it is combined with Piperine.
Pirtobrutinib
The serum concentration of Umeclidinium can be increased when it is combined with Pirtobrutinib.
Pitolisant
The serum concentration of Vilanterol can be decreased when it is combined with Pitolisant.
Plazomicin
Vilanterol may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Polythiazide
The risk or severity of hypokalemia can be increased when Polythiazide is combined with Vilanterol.
Pomalidomide
The serum concentration of Pomalidomide can be increased when it is combined with Umeclidinium.
Posaconazole
The serum concentration of Umeclidinium can be increased when it is combined with Posaconazole.
Posaconazole
The serum concentration of Vilanterol can be increased when it is combined with Posaconazole.
Pralsetinib
The serum concentration of Umeclidinium can be increased when it is combined with Pralsetinib.
Pravastatin
The serum concentration of Umeclidinium can be increased when it is combined with Pravastatin.
Prazosin
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Prazosin.
Prednisolone acetate
The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Vilanterol.
Prednisolone phosphate
The serum concentration of Prednisolone phosphate can be increased when it is combined with Umeclidinium.
Prednisolone phosphate
The risk or severity of hypokalemia can be increased when Prednisolone phosphate is combined with Vilanterol.
Pregabalin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Pregabalin.
Pretomanid
The serum concentration of Umeclidinium can be increased when it is combined with Pretomanid.
Primaquine
The metabolism of Umeclidinium can be decreased when combined with Primaquine.
Primaquine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Primaquine.
Procainamide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Procainamide.
Procaine
The risk or severity of hypertension and cardiovascular complications can be increased when Procaine is combined with Vilanterol.
Procarbazine
The risk or severity of hypertension and cardiovascular complications can be increased when Procarbazine is combined with Vilanterol.
Prochlorperazine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Prochlorperazine.
Promethazine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Promethazine.
Propafenone
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Propafenone.
Propofol
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Propofol.
Propranolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Propranolol.
Protriptyline
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Protriptyline.
Protriptyline
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Protriptyline.
Quetiapine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Quetiapine.
Quinidine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Quinidine.
Quinine
The metabolism of Umeclidinium can be decreased when combined with Quinine.
Quinine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Quinine.
Quizartinib
The serum concentration of Umeclidinium can be increased when it is combined with Quizartinib.
Quizartinib
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Quizartinib.
Rabies immune globulin, human
The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Vilanterol.
Rabies virus inactivated antigen, A
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Vilanterol.
Rabies virus inactivated antigen, B
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Vilanterol.
Racepinephrine
The risk or severity of adverse effects can be increased when Vilanterol is combined with Racepinephrine.
Ranitidine
The metabolism of Umeclidinium can be decreased when combined with Ranitidine.
Ranolazine
The serum concentration of Umeclidinium can be increased when it is combined with Ranolazine.
Ranolazine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Ranolazine.
Rasagiline
The risk or severity of hypertension and cardiovascular complications can be increased when Rasagiline is combined with Vilanterol.
Regorafenib
The serum concentration of Umeclidinium can be increased when it is combined with Regorafenib.
Relugolix
The serum concentration of Relugolix can be increased when it is combined with Umeclidinium.
Remifentanil
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Remifentanil.
Repotrectinib
The serum concentration of Umeclidinium can be increased when it is combined with Repotrectinib.
Reserpine
The serum concentration of Umeclidinium can be increased when it is combined with Reserpine.
Respiratory syncytial virus vaccine, adjuvanted
The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Vilanterol.
Revumenib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Revumenib.
Ribociclib
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Vilanterol.
Rilonacept
The metabolism of Umeclidinium can be increased when combined with Rilonacept.
Rilpivirine
The metabolism of Umeclidinium can be decreased when combined with Rilpivirine.
Rilpivirine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Rilpivirine.
Rimegepant
The serum concentration of Rimegepant can be increased when it is combined with Umeclidinium.
Riociguat
The serum concentration of Umeclidinium can be increased when it is combined with Riociguat.
Ripretinib
The serum concentration of Umeclidinium can be increased when it is combined with Ripretinib.
Risperidone
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Risperidone.
Ritlecitinib
The serum concentration of Vilanterol can be increased when it is combined with Ritlecitinib.
Ritonavir
The metabolism of Umeclidinium can be decreased when combined with Ritonavir.
Ritonavir
The serum concentration of Vilanterol can be increased when it is combined with Ritonavir.
Rivaroxaban
The serum concentration of Umeclidinium can be increased when it is combined with Rivaroxaban.
Rolapitant
The metabolism of Umeclidinium can be decreased when combined with Rolapitant.
Romidepsin
The serum concentration of Romidepsin can be increased when it is combined with Umeclidinium.
Romidepsin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Romidepsin.
Ropeginterferon alfa-2b
The metabolism of Umeclidinium can be decreased when combined with Ropeginterferon alfa-2b.
Rotavirus vaccine
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Vilanterol.
Rucaparib
The metabolism of Umeclidinium can be decreased when combined with Rucaparib.
Safinamide
The risk or severity of hypertension and cardiovascular complications can be increased when Safinamide is combined with Vilanterol.
Salmeterol
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Salmeterol.
Sapropterin
The serum concentration of Umeclidinium can be increased when it is combined with Sapropterin.
Saquinavir
The serum concentration of Umeclidinium can be increased when it is combined with Saquinavir.
Saquinavir
The serum concentration of Vilanterol can be increased when it is combined with Saquinavir.
Sarecycline
The serum concentration of Umeclidinium can be increased when it is combined with Sarecycline.
Satralizumab
The serum concentration of Vilanterol can be decreased when it is combined with Satralizumab.
Secukinumab
The metabolism of Umeclidinium can be increased when combined with Secukinumab.
Selegiline
The risk or severity of hypertension and cardiovascular complications can be increased when Selegiline is combined with Vilanterol.
Selexipag
The serum concentration of Selexipag can be increased when it is combined with Umeclidinium.
Selpercatinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Selpercatinib.
Selumetinib
The serum concentration of Selumetinib can be increased when it is combined with Umeclidinium.
Sertraline
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Sertraline.
Sevoflurane
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Sevoflurane.
Sildenafil
The serum concentration of Umeclidinium can be increased when it is combined with Sildenafil.
Silodosin
The serum concentration of Umeclidinium can be increased when it is combined with Silodosin.
Silodosin
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Silodosin.
Siltuximab
The metabolism of Umeclidinium can be increased when combined with Siltuximab.
Simvastatin
The serum concentration of Umeclidinium can be increased when it is combined with Simvastatin.
Sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vilanterol.
Sirolimus
The serum concentration of Sirolimus can be increased when it is combined with Umeclidinium.
Sitagliptin
The serum concentration of Umeclidinium can be increased when it is combined with Sitagliptin.
Sofosbuvir
The serum concentration of Umeclidinium can be increased when it is combined with Sofosbuvir.
Sofpironium
Sofpironium may increase the anticholinergic activities of Umeclidinium.
Solifenacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Solifenacin.
Solriamfetol
The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Umeclidinium.
Solriamfetol
The risk or severity of hypertension can be increased when Solriamfetol is combined with Vilanterol.
Sorafenib
The serum concentration of Umeclidinium can be increased when it is combined with Sorafenib.
Sorafenib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Sorafenib.
Sotagliflozin
The serum concentration of Umeclidinium can be increased when it is combined with Sotagliflozin.
Sotalol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Sotalol.
Sotorasib
The serum concentration of Umeclidinium can be increased when it is combined with Sotorasib.
Sotorasib
The serum concentration of Vilanterol can be decreased when it is combined with Sotorasib.
Sparsentan
The serum concentration of Umeclidinium can be increased when it is combined with Sparsentan.
Spironolactone
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Spironolactone.
Stiripentol
The metabolism of Vilanterol can be decreased when combined with Stiripentol.
Streptomycin
Vilanterol may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Sufentanil
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Sufentanil.
Sulfamethoxazole
The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Vilanterol.
Sunitinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Sunitinib.
Suvorexant
The serum concentration of Umeclidinium can be increased when it is combined with Suvorexant.
Tacrolimus
The serum concentration of Umeclidinium can be increased when it is combined with Tacrolimus.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Vilanterol.
Talazoparib
The serum concentration of Talazoparib can be increased when it is combined with Umeclidinium.
Taletrectinib
The serum concentration of Umeclidinium can be increased when it is combined with Taletrectinib.
Taletrectinib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Taletrectinib.
Tamoxifen
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Tamoxifen.
Tamsulosin
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Tamsulosin.
Tazemetostat
The serum concentration of Tazemetostat can be increased when it is combined with Umeclidinium.
Technetium Tc-99m sestamibi
The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Umeclidinium.
Tegaserod
The metabolism of Umeclidinium can be decreased when combined with Tegaserod.
Telavancin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Telavancin.
Telithromycin
The serum concentration of Vilanterol can be increased when it is combined with Telithromycin.
Telotristat ethyl
The serum concentration of Umeclidinium can be increased when it is combined with Telotristat ethyl.
Telotristat ethyl
The serum concentration of Vilanterol can be decreased when it is combined with Telotristat ethyl.
Temsirolimus
The serum concentration of Umeclidinium can be increased when it is combined with Temsirolimus.
Tenofovir alafenamide
The serum concentration of Tenofovir alafenamide can be increased when it is combined with Vilanterol.
Tenofovir disoproxil
The serum concentration of Umeclidinium can be increased when it is combined with Tenofovir disoproxil.
Tepotinib
The serum concentration of Umeclidinium can be increased when it is combined with Tepotinib.
Terazosin
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Terazosin.
Terbinafine
The metabolism of Umeclidinium can be decreased when combined with Terbinafine.
Terbutaline
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Terbutaline.
Terlipressin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Terlipressin.
Testosterone undecanoate
Testosterone undecanoate may increase the hypertensive activities of Vilanterol.
Tetrabenazine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Tetrabenazine.
Tezacaftor
The serum concentration of Tezacaftor can be increased when it is combined with Umeclidinium.
Thioridazine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Thioridazine.
Thiothixene
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Thiothixene.
Ticagrelor
The serum concentration of Umeclidinium can be increased when it is combined with Ticagrelor.
Tick-borne encephalitis vaccine (whole virus, inactivated)
The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Vilanterol.
Ticlopidine
The metabolism of Umeclidinium can be decreased when combined with Ticlopidine.
Timolol
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Timolol.
Tipranavir
The metabolism of Umeclidinium can be decreased when combined with Tipranavir.
Tipranavir
The serum concentration of Vilanterol can be increased when it is combined with Tipranavir.
Tivozanib
The serum concentration of Tivozanib can be increased when it is combined with Umeclidinium.
Tizanidine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Tizanidine.
Tobramycin
Vilanterol may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocilizumab
The metabolism of Umeclidinium can be increased when combined with Tocilizumab.
Tofacitinib
Vilanterol may increase the immunosuppressive activities of Tofacitinib.
Tolterodine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Tolterodine.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Umeclidinium.
Topiramate
The risk or severity of hyperthermia and oligohydrosis can be increased when Umeclidinium is combined with Topiramate.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Umeclidinium.
Torasemide
The risk or severity of hypokalemia can be increased when Torasemide is combined with Vilanterol.
Toremifene
The serum concentration of Umeclidinium can be increased when it is combined with Toremifene.
Toremifene
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Toremifene.
Tranylcypromine
The metabolism of Umeclidinium can be decreased when combined with Tranylcypromine.
Tranylcypromine
The risk or severity of hypertension and cardiovascular complications can be increased when Tranylcypromine is combined with Vilanterol.
Trastuzumab
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Vilanterol.
Trastuzumab emtansine
The serum concentration of Trastuzumab emtansine can be increased when it is combined with Umeclidinium.
Treprostinil
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Treprostinil.
Triclabendazole
The metabolism of Umeclidinium can be decreased when combined with Triclabendazole.
Triclabendazole
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Triclabendazole.
Trifluoperazine
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Trifluoperazine.
Trilaciclib
The serum concentration of Trilaciclib can be increased when it is combined with Umeclidinium.
Trimipramine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Trimipramine.
Triprolidine
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Triprolidine.
Triptorelin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Triptorelin.
Trovafloxacin
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Trovafloxacin.
Tucatinib
Tucatinib may decrease the excretion rate of Umeclidinium which could result in a higher serum level.
Tucatinib
The metabolism of Tucatinib can be decreased when combined with Vilanterol.
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Vilanterol.
Typhoid Vi polysaccharide vaccine
The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Vilanterol.
Ublituximab
The risk or severity of infection can be increased when Ublituximab is combined with Vilanterol.
Ubrogepant
The serum concentration of Ubrogepant can be increased when it is combined with Umeclidinium.
Valproic acid
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Valproic acid.
Vamorolone
The risk or severity of hypokalemia can be increased when Vamorolone is combined with Vilanterol.
Vancomycin
Vilanterol may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Vandetanib
The serum concentration of Umeclidinium can be increased when it is combined with Vandetanib.
Vandetanib
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Vandetanib.
Vardenafil
The serum concentration of Umeclidinium can be increased when it is combined with Vardenafil.
Vardenafil
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Vardenafil.
Varicella zoster vaccine (recombinant)
The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Vilanterol.
Velpatasvir
The serum concentration of Umeclidinium can be increased when it is combined with Velpatasvir.
Vemurafenib
The serum concentration of Umeclidinium can be increased when it is combined with Vemurafenib.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Vilanterol.
Venetoclax
The serum concentration of Umeclidinium can be increased when it is combined with Venetoclax.
Venetoclax
The metabolism of Vilanterol can be decreased when combined with Venetoclax.
Venlafaxine
Venlafaxine may increase the tachycardic activities of Vilanterol.
Verapamil
The serum concentration of Umeclidinium can be increased when it is combined with Verapamil.
Verapamil
The metabolism of Vilanterol can be decreased when combined with Verapamil.
Vilazodone
The metabolism of Umeclidinium can be decreased when combined with Vilazodone.
Vimseltinib
The serum concentration of Umeclidinium can be increased when it is combined with Vimseltinib.
Vinblastine
The serum concentration of Vinblastine can be increased when it is combined with Umeclidinium.
Vincristine
The serum concentration of Vincristine can be increased when it is combined with Umeclidinium.
Voclosporin
The serum concentration of Umeclidinium can be increased when it is combined with Voclosporin.
Vorapaxar
The serum concentration of Umeclidinium can be increased when it is combined with Vorapaxar.
Voriconazole
The serum concentration of Vilanterol can be increased when it is combined with Voriconazole.
Vorinostat
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Vorinostat.
Voxilaprevir
The serum concentration of Umeclidinium can be increased when it is combined with Voxilaprevir.
Warfarin
Vilanterol may decrease the excretion rate of Warfarin which could result in a higher serum level.
Zonisamide
The serum concentration of Umeclidinium can be increased when it is combined with Zonisamide.
Zonisamide
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Zonisamide.
Abacavir
Abacavir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Aceclofenac
The risk or severity of hypertension can be increased when Aceclofenac is combined with Vilanterol.
Acetaminophen
The metabolism of Umeclidinium can be decreased when combined with Acetaminophen.
Acetaminophen
Acetaminophen may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Acetazolamide
Acetazolamide may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid
The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Vilanterol.
Aclidinium
Aclidinium may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Acyclovir
Acyclovir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Adefovir dipivoxil
Adefovir dipivoxil may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Adenosine
The risk or severity of Tachycardia can be increased when Adenosine is combined with Umeclidinium.
Albuterol
The risk or severity of Tachycardia can be increased when Salbutamol is combined with Umeclidinium.
Albutrepenonacog alfa
Vilanterol may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alfentanil
The risk or severity of hypertension can be increased when Alfentanil is combined with Vilanterol.
Aliskiren
Vilanterol may decrease the antihypertensive activities of Aliskiren.
Allogeneic processed thymus tissue
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Vilanterol.
Allopurinol
Allopurinol may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Almasilate
Vilanterol may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan
The metabolism of Umeclidinium can be decreased when combined with Almotriptan.
Almotriptan
The risk or severity of hypertension can be increased when Almotriptan is combined with Vilanterol.
Alogliptin
The metabolism of Umeclidinium can be decreased when combined with Alogliptin.
Alogliptin
Alogliptin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Alprazolam
Alprazolam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Amantadine
The risk or severity of adverse effects can be increased when Amantadine is combined with Umeclidinium.
Ambrisentan
Vilanterol may decrease the antihypertensive activities of Ambrisentan.
Amiloride
Amiloride may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Aminophylline
The risk or severity of hypokalemia can be increased when Aminophylline is combined with Vilanterol.
Amlodipine
Vilanterol may decrease the antihypertensive activities of Amlodipine.
Ammonium chloride
Ammonium chloride may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Amobarbital
The risk or severity of adverse effects can be increased when Amobarbital is combined with Umeclidinium.
Amoxicillin
Amoxicillin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Amphetamine
The metabolism of Umeclidinium can be decreased when combined with Amphetamine.
Amphetamine
The risk or severity of hypertension can be increased when Amphetamine is combined with Vilanterol.
Amphotericin B
Amphotericin B may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ampicillin
Ampicillin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Anagrelide
The risk or severity of Tachycardia can be increased when Anagrelide is combined with Umeclidinium.
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Vilanterol.
Antipyrine
The metabolism of Umeclidinium can be decreased when combined with Antipyrine.
Antipyrine
The risk or severity of hypertension can be increased when Antipyrine is combined with Vilanterol.
Antithrombin III human
Vilanterol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Aprocitentan
Vilanterol may decrease the antihypertensive activities of Aprocitentan.
Arformoterol
The metabolism of Umeclidinium can be decreased when combined with Arformoterol.
Aripiprazole lauroxil
The metabolism of Aripiprazole lauroxil can be decreased when combined with Umeclidinium.
Atenolol
The metabolism of Umeclidinium can be decreased when combined with Atenolol.
Atomoxetine
The metabolism of Umeclidinium can be decreased when combined with Atomoxetine.
Atracurium besylate
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Umeclidinium.
Auranofin
Auranofin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Azelaic acid
Azelaic acid may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Azelastine
The metabolism of Umeclidinium can be decreased when combined with Azelastine.
Azilsartan medoxomil
Vilanterol may decrease the antihypertensive activities of Azilsartan medoxomil.
Aztreonam
Aztreonam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Bacitracin
Bacitracin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Baclofen
Baclofen may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Balsalazide
The risk or severity of hypertension can be increased when Balsalazide is combined with Vilanterol.
Benazepril
Vilanterol may decrease the antihypertensive activities of Benazepril.
Bendroflumethiazide
The serum concentration of Bendroflumethiazide can be increased when it is combined with Umeclidinium.
Benzgalantamine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Benzgalantamine.
Benznidazole
Vilanterol may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzocaine
The metabolism of Umeclidinium can be decreased when combined with Benzocaine.
Benzphetamine
The risk or severity of Tachycardia can be increased when Benzphetamine is combined with Umeclidinium.
Benzphetamine
The risk or severity of hypertension can be increased when Benzphetamine is combined with Vilanterol.
Benzyl alcohol
The metabolism of Umeclidinium can be decreased when combined with Benzyl alcohol.
Bepotastine
Bepotastine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Betaine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Betaine.
Betaxolol
The metabolism of Umeclidinium can be decreased when combined with Betaxolol.
Bicisate
Vilanterol may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bisacodyl
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Umeclidinium.
Bismuth subgallate
Vilanterol may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bosentan
Vilanterol may decrease the antihypertensive activities of Bosentan.
Brexpiprazole
The metabolism of Brexpiprazole can be decreased when combined with Umeclidinium.
Brivaracetam
Brivaracetam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Bromocriptine
The risk or severity of Tachycardia can be increased when Bromocriptine is combined with Umeclidinium.
Bromotheophylline
Bromotheophylline may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Bupivacaine
The metabolism of Umeclidinium can be decreased when combined with Bupivacaine.
Bupropion
Bupropion may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Buspirone
The metabolism of Umeclidinium can be decreased when combined with Buspirone.
Buspirone
The risk or severity of hypertension can be increased when Buspirone is combined with Vilanterol.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Umeclidinium.
Caffeine
The risk or severity of hypokalemia can be increased when Caffeine is combined with Vilanterol.
Calcium polycarbophil
The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Umeclidinium.
Canagliflozin
Canagliflozin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Candesartan cilexetil
Vilanterol may decrease the antihypertensive activities of Candesartan cilexetil.
Cannabidiol
The risk or severity of hypertension can be increased when Cannabidiol is combined with Vilanterol.
Capsaicin
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Capsaicin.
Captopril
Vilanterol may decrease the antihypertensive activities of Captopril.
Carbidopa
Carbidopa may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Carboxymethylcellulose
The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Umeclidinium.
Cariprazine
The risk or severity of hypertension can be increased when Cariprazine is combined with Vilanterol.
Castor oil
The therapeutic efficacy of Castor oil can be decreased when used in combination with Umeclidinium.
Cefaclor
Cefaclor may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefadroxil
Cefadroxil may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefazolin
Cefazolin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefdinir
Cefdinir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefditoren
Cefditoren may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefepime
Cefepime may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefotaxime
Cefotaxime may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefotetan
Cefotetan may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefoxitin
Cefoxitin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefpodoxime
Cefpodoxime may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefprozil
Cefprozil may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ceftaroline fosamil
Ceftaroline fosamil may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ceftazidime
Ceftazidime may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ceftibuten
Ceftibuten may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ceftizoxime
Ceftizoxime may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ceftolozane
Ceftolozane may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ceftriaxone
Ceftriaxone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cefuroxime
Cefuroxime may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Celecoxib
The risk or severity of hypertension can be increased when Celecoxib is combined with Vilanterol.
Cephalexin
Cephalexin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cetirizine
Umeclidinium may increase the anticholinergic activities of Cetirizine.
Cevimeline
The metabolism of Umeclidinium can be decreased when combined with Cevimeline.
Cevimeline
Cevimeline may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Chlorothiazide
The serum concentration of Chlorothiazide can be increased when it is combined with Umeclidinium.
Chlorthalidone
The serum concentration of Chlorthalidone can be increased when it is combined with Umeclidinium.
Chlorthalidone
Vilanterol may decrease the antihypertensive activities of Chlorthalidone.
Chlorzoxazone
The metabolism of Umeclidinium can be decreased when combined with Chlorzoxazone.
Chlorzoxazone
Chlorzoxazone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Choline salicylate
Vilanterol may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate
Vilanterol may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride
Vilanterol may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromium
Vilanterol may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium nicotinate
Vilanterol may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Ciclesonide
The metabolism of Umeclidinium can be decreased when combined with Ciclesonide.
Cidofovir
Cidofovir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cilostazol
The metabolism of Umeclidinium can be decreased when combined with Cilostazol.
Cimetidine
The metabolism of Umeclidinium can be decreased when combined with Cimetidine.
Cimetidine
Cimetidine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cinchocaine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Cinchocaine.
Cisatracurium
The risk or severity of adverse effects can be increased when Cisatracurium is combined with Umeclidinium.
Cisplatin
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Cisplatin.
Cladribine
Vilanterol may increase the immunosuppressive activities of Cladribine.
Clevidipine
The metabolism of Umeclidinium can be decreased when combined with Clevidipine.
Clevidipine
Clevidipine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Clidinium
The risk or severity of Tachycardia can be increased when Clidinium is combined with Vilanterol.
Clobazam
Clobazam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Clonazepam
Clonazepam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Clonidine
Vilanterol may decrease the antihypertensive activities of Clonidine.
Clorazepic acid
Clorazepic acid may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Clove oil
Vilanterol may decrease the excretion rate of Clove oil which could result in a higher serum level.
Colchicine
Colchicine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Colistimethate
Colistimethate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Conjugated estrogens
Conjugated estrogens may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cyanocobalamin
Cyanocobalamin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Cyclopentolate
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Umeclidinium.
Dabigatran etexilate
Dabigatran etexilate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Dalfampridine
Dalfampridine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Daptomycin
Daptomycin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Darifenacin
The risk or severity of Tachycardia can be increased when Darifenacin is combined with Vilanterol.
Dasiglucagon
Vilanterol may decrease the antihypertensive activities of Dasiglucagon.
DaxibotulinumtoxinA
Umeclidinium may increase the neuromuscular blocking activities of DaxibotulinumtoxinA.
Deferiprone
Deferiprone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Umeclidinium.
Desmopressin
The risk or severity of hypertension can be increased when Desmopressin is combined with Vilanterol.
Desvenlafaxine
The serum concentration of Umeclidinium can be increased when it is combined with Desvenlafaxine.
Deutetrabenazine
The metabolism of Deutetrabenazine can be decreased when combined with Umeclidinium.
Dexmedetomidine
The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Vilanterol.
Dexmethylphenidate
The risk or severity of hypertension can be increased when Dexmethylphenidate is combined with Vilanterol.
Dexpanthenol
Vilanterol may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dextran
Vilanterol may decrease the excretion rate of Dextran which could result in a higher serum level.
Dextroamphetamine
The metabolism of Umeclidinium can be decreased when combined with Dextroamphetamine.
Dextroamphetamine
The risk or severity of hypertension can be increased when Dextroamphetamine is combined with Vilanterol.
Dextromethorphan
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Umeclidinium.
Diatrizoate
Diatrizoate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Diazepam
Diazepam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Diazoxide
Vilanterol may decrease the antihypertensive activities of Diazoxide.
Diclofenac
The risk or severity of hypertension can be increased when Diclofenac is combined with Vilanterol.
Diclofenamide
Diclofenamide may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Dicyclomine
Dicyclomine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Didanosine
Didanosine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Dienogest
Vilanterol may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diethylpropion
The risk or severity of Tachycardia can be increased when Diethylpropion is combined with Umeclidinium.
Diethylpropion
The risk or severity of hypertension can be increased when Diethylpropion is combined with Vilanterol.
Diflunisal
The risk or severity of hypertension can be increased when Diflunisal is combined with Vilanterol.
Diltiazem
The metabolism of Umeclidinium can be decreased when combined with Diltiazem.
Dimercaprol
Dimercaprol may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Dimethyl sulfoxide
Dimethyl sulfoxide may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Dipotassium phosphate
The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Umeclidinium.
DL-Methylephedrine
The risk or severity of Tachycardia can be increased when Umeclidinium is combined with DL-Methylephedrine.
DL-Methylephedrine
The risk or severity of hypertension can be increased when Vilanterol is combined with DL-Methylephedrine.
Dobutamine
The risk or severity of Tachycardia can be increased when Dobutamine is combined with Umeclidinium.
Docusate
The therapeutic efficacy of Docusate can be decreased when used in combination with Umeclidinium.
Dolasetron
The metabolism of Umeclidinium can be decreased when combined with Dolasetron.
Dopamine
The risk or severity of Tachycardia can be increased when Dopamine is combined with Umeclidinium.
Dopamine
The risk or severity of hypertension can be increased when Dopamine is combined with Vilanterol.
Doxapram
The risk or severity of hypertension can be increased when Doxapram is combined with Vilanterol.
Doxazosin
The metabolism of Umeclidinium can be decreased when combined with Doxazosin.
Doxycycline
Doxycycline may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Dronabinol
The risk or severity of Tachycardia can be increased when Dronabinol is combined with Vilanterol.
Dronedarone
The metabolism of Umeclidinium can be decreased when combined with Dronedarone.
Drospirenone
Drospirenone may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Droxidopa
The risk or severity of Tachycardia can be increased when Droxidopa is combined with Umeclidinium.
Dutasteride
The risk or severity of hypertension can be increased when Dutasteride is combined with Vilanterol.
Edoxaban
Edoxaban may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Edrophonium
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Edrophonium.
Edrophonium
Edrophonium may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Eletriptan
The metabolism of Umeclidinium can be decreased when combined with Eletriptan.
Eletriptan
The risk or severity of hypertension can be increased when Eletriptan is combined with Vilanterol.
Enalapril
Vilanterol may decrease the antihypertensive activities of Enalapril.
Enalaprilat
Vilanterol may decrease the antihypertensive activities of Enalaprilat.
Entacapone
The metabolism of Umeclidinium can be decreased when combined with Entacapone.
Ephedrine
The risk or severity of Tachycardia can be increased when Ephedrine is combined with Umeclidinium.
Ephedrine
The risk or severity of hypertension can be increased when Ephedrine is combined with Vilanterol.
Epinastine
The metabolism of Umeclidinium can be decreased when combined with Epinastine.
Epinephrine
The risk or severity of Tachycardia can be increased when Epinephrine is combined with Umeclidinium.
Eplerenone
Vilanterol may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
Vilanterol may decrease the antihypertensive activities of Epoprostenol.
Eprosartan
Vilanterol may decrease the antihypertensive activities of Eprosartan.
Ertapenem
Ertapenem may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Esketamine
The risk or severity of Tachycardia can be increased when Umeclidinium is combined with Esketamine.
Esmolol
The metabolism of Umeclidinium can be decreased when combined with Esmolol.
Estazolam
Estazolam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Estradiol
Estradiol may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Estradiol acetate
Vilanterol may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypionate
Vilanterol may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol valerate
Vilanterol may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Estrone sulfate
Estrone sulfate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Eszopiclone
Eszopiclone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ethambutol
The metabolism of Umeclidinium can be decreased when combined with Ethambutol.
Ethambutol
Ethambutol may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ethenzamide
The risk or severity of hypertension can be increased when Vilanterol is combined with Ethenzamide.
Etodolac
The risk or severity of hypertension can be increased when Etodolac is combined with Vilanterol.
Etomidate
The risk or severity of Tachycardia can be increased when Etomidate is combined with Umeclidinium.
Etomidate
The risk or severity of hypertension can be increased when Etomidate is combined with Vilanterol.
Etonogestrel
Etonogestrel may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Eucalyptus oil
Vilanterol may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Evening primrose oil
Vilanterol may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
Fenofibrate
Fenofibrate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Fenofibric acid
Vilanterol may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam
Vilanterol may decrease the antihypertensive activities of Fenoldopam.
Fenoprofen
The risk or severity of hypertension can be increased when Fenoprofen is combined with Vilanterol.
Fentanyl
The risk or severity of hypertension can be increased when Fentanyl is combined with Vilanterol.
Fesoterodine
Fesoterodine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Fexinidazole
The metabolism of Fexinidazole can be decreased when combined with Umeclidinium.
Finasteride
The risk or severity of hypertension can be increased when Finasteride is combined with Vilanterol.
Finerenone
Finerenone may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Flavoxate
Flavoxate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Flibanserin
The risk or severity of hypertension can be increased when Flibanserin is combined with Vilanterol.
Florbetaben F-18
Vilanterol may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir F-18
Vilanterol may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Fludeoxyglucose (18F)
Vilanterol may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Flumazenil
Flumazenil may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Fluphenazine
The metabolism of Umeclidinium can be decreased when combined with Fluphenazine.
Flurazepam
Flurazepam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Flurbiprofen
The risk or severity of hypertension can be increased when Flurbiprofen is combined with Vilanterol.
Flutamide
Flutamide may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Fluvastatin
The metabolism of Umeclidinium can be decreased when combined with Fluvastatin.
Folic acid
Folic acid may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Fomepizole
Fomepizole may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Fondaparinux
Fondaparinux may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Formoterol
The metabolism of Umeclidinium can be decreased when combined with Formoterol.
Fosfomycin
Fosfomycin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Fosinopril
Vilanterol may decrease the antihypertensive activities of Fosinopril.
Fostemsavir
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Fostemsavir.
Frangula purshiana bark
The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Umeclidinium.
Frovatriptan
The risk or severity of hypertension can be increased when Frovatriptan is combined with Vilanterol.
Gabapentin enacarbil
Gabapentin enacarbil may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Gadodiamide
Gadodiamide may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Gadofosveset trisodium
Gadofosveset trisodium may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Gadoteric acid
Vilanterol may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol
Gadoteridol may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Galantamine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Galantamine.
Ganciclovir
Ganciclovir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Gefitinib
The metabolism of Umeclidinium can be decreased when combined with Gefitinib.
Gemfibrozil
Gemfibrozil may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ginkgo biloba
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Ginkgo biloba.
Givosiran
Givosiran may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Glipizide
Glipizide may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Glycerin
The therapeutic efficacy of Glycerin can be decreased when used in combination with Umeclidinium.
Glycerol phenylbutyrate
Glycerol phenylbutyrate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Glycopyrronium
The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Vilanterol.
Golodirsen
Vilanterol may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Guanfacine
The risk or severity of Tachycardia can be increased when Guanfacine is combined with Umeclidinium.
Guanfacine
Vilanterol may decrease the antihypertensive activities of Guanfacine.
Homatropine
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Homatropine.
Homatropine methylbromide
The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Vilanterol.
Hydralazine
Vilanterol may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The serum concentration of Hydrochlorothiazide can be increased when it is combined with Umeclidinium.
Hydroflumethiazide
The serum concentration of Hydroflumethiazide can be increased when it is combined with Umeclidinium.
Hydromorphone
Hydromorphone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Hydroxocobalamin
Hydroxocobalamin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Hydroxyethyl Starch
Vilanterol may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Ibrutinib
The metabolism of Umeclidinium can be decreased when combined with Ibrutinib.
Ibuprofen
The risk or severity of hypertension can be increased when Ibuprofen is combined with Vilanterol.
Icatibant
Icatibant may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Icosapent
The risk or severity of hypertension can be increased when Icosapent is combined with Vilanterol.
Idarubicin
The metabolism of Umeclidinium can be decreased when combined with Idarubicin.
Idarucizumab
Vilanterol may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Iloperidone
The metabolism of Umeclidinium can be decreased when combined with Iloperidone.
Imatinib
The serum concentration of Umeclidinium can be increased when it is combined with Imatinib.
Indapamide
The serum concentration of Indapamide can be increased when it is combined with Umeclidinium.
Indigotindisulfonic acid
Vilanterol may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Inebilizumab
The risk or severity of infection can be increased when Vilanterol is combined with Inebilizumab.
Inositol
Vilanterol may decrease the excretion rate of Inositol which could result in a higher serum level.
Iobenguane sulfate I-123
Vilanterol may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iodixanol
Iodixanol may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ioflupane I-123
Ioflupane I-123 may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Iopromide
Vilanterol may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid
Vilanterol may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol
Vilanterol may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ipecac
The metabolism of Ipecac can be decreased when combined with Umeclidinium.
Ipecac
Vilanterol may decrease the excretion rate of Ipecac which could result in a higher serum level.
Ipilimumab
Ipilimumab may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ipratropium
The risk or severity of Tachycardia can be increased when Ipratropium is combined with Vilanterol.
Iptacopan
The metabolism of Iptacopan can be decreased when combined with Umeclidinium.
Irbesartan
Vilanterol may decrease the antihypertensive activities of Irbesartan.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Umeclidinium.
Isoprenaline
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Isoprenaline.
Isosorbide
Isosorbide may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide mononitrate
Isosorbide mononitrate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Isosulfan blue
Vilanterol may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin
Isotretinoin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Isoxsuprine
The risk or severity of Tachycardia can be increased when Isoxsuprine is combined with Umeclidinium.
Isoxsuprine
The risk or severity of hypertension can be increased when Isoxsuprine is combined with Vilanterol.
Ixazomib
Vilanterol may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Ketamine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Ketamine.
Ketamine
Ketamine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ketoprofen
The risk or severity of hypertension can be increased when Ketoprofen is combined with Vilanterol.
Ketorolac
The risk or severity of hypertension can be increased when Ketorolac is combined with Vilanterol.
L-Acetylleucine
The serum concentration of Umeclidinium can be increased when it is combined with L-Acetylleucine.
Lactitol
The therapeutic efficacy of Lactitol can be decreased when used in combination with Umeclidinium.
Lactulose
The therapeutic efficacy of Lactulose can be decreased when used in combination with Umeclidinium.
Lamivudine
Lamivudine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Lamotrigine
The risk or severity of Tachycardia can be increased when Lamotrigine is combined with Umeclidinium.
Lansoprazole
The metabolism of Umeclidinium can be decreased when combined with Lansoprazole.
Ledipasvir
Ledipasvir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Levamlodipine
Vilanterol may decrease the antihypertensive activities of Levamlodipine.
Levocarnitine
Levocarnitine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Levocetirizine
Umeclidinium may increase the anticholinergic activities of Levocetirizine.
Levomenthol
The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Vilanterol.
Levomilnacipran
The risk or severity of Tachycardia can be increased when Levomilnacipran is combined with Umeclidinium.
Levonordefrin
The risk or severity of Tachycardia can be increased when Levonordefrin is combined with Umeclidinium.
Levonordefrin
The risk or severity of hypertension can be increased when Levonordefrin is combined with Vilanterol.
Levosalbutamol
The risk or severity of Tachycardia can be increased when Umeclidinium is combined with Levosalbutamol.
Linaclotide
The therapeutic efficacy of Linaclotide can be decreased when used in combination with Umeclidinium.
Liothyronine
Liothyronine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Lisdexamfetamine
The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Umeclidinium.
Lisdexamfetamine
The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Vilanterol.
Lisinopril
Vilanterol may decrease the antihypertensive activities of Lisinopril.
Lithium citrate
Lithium citrate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Lixisenatide
Vilanterol may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Lofexidine
The metabolism of Umeclidinium can be decreased when combined with Lofexidine.
Loratadine
Umeclidinium may increase the anticholinergic activities of Loratadine.
Loratadine
The risk or severity of QTc prolongation can be increased when Loratadine is combined with Vilanterol.
Lorazepam
Lorazepam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Losartan
Vilanterol may decrease the antihypertensive activities of Losartan.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Umeclidinium.
Lubiprostone
Lubiprostone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Macitentan
Vilanterol may decrease the antihypertensive activities of Macitentan.
Magnesium
The therapeutic efficacy of Magnesium can be decreased when used in combination with Umeclidinium.
Magnesium carbonate
The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Umeclidinium.
Magnesium carbonate
Vilanterol may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chloride
Vilanterol may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium citrate
The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Umeclidinium.
Magnesium glycinate
The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Umeclidinium.
Magnesium hydroxide
The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Umeclidinium.
Magnesium hydroxide
Vilanterol may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium oxide
The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Umeclidinium.
Magnesium salicylate
The risk or severity of hypertension can be increased when Magnesium salicylate is combined with Vilanterol.
Magnesium sulfate
The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Umeclidinium.
Magnesium trisilicate
The therapeutic efficacy of Magnesium trisilicate can be decreased when used in combination with Umeclidinium.
Magnesium trisilicate
Vilanterol may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mannitol
Mannitol may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Mavorixafor
The risk or severity of QTc prolongation can be increased when Mavorixafor is combined with Vilanterol.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Umeclidinium.
Mecamylamine
Vilanterol may decrease the antihypertensive activities of Mecamylamine.
Mechlorethamine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Mechlorethamine.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Umeclidinium.
Meclofenamic acid
The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Vilanterol.
Medroxyprogesterone acetate
Medroxyprogesterone acetate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Mefenamic acid
The risk or severity of hypertension can be increased when Mefenamic acid is combined with Vilanterol.
Megestrol acetate
Megestrol acetate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Meloxicam
The risk or severity of hypertension can be increased when Meloxicam is combined with Vilanterol.
Memantine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Memantine.
Memantine
Memantine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Meperidine
Meperidine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Mepivacaine
Mepivacaine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Meropenem
Meropenem may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Mesalazine
The risk or severity of hypertension can be increased when Mesalazine is combined with Vilanterol.
Metamfetamine
The metabolism of Umeclidinium can be decreased when combined with Metamfetamine.
Metamfetamine
The risk or severity of hypertension can be increased when Metamfetamine is combined with Vilanterol.
Metaraminol
The risk or severity of Tachycardia can be increased when Metaraminol is combined with Umeclidinium.
Metaraminol
The risk or severity of hypertension can be increased when Metaraminol is combined with Vilanterol.
Metaxalone
Metaxalone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Metformin
Metformin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Methazolamide
Methazolamide may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Methoxsalen
Methoxsalen may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Methscopolamine bromide
The risk or severity of Tachycardia can be increased when Methscopolamine bromide is combined with Vilanterol.
Methylcellulose
The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Umeclidinium.
Methyldopa
Vilanterol may decrease the antihypertensive activities of Methyldopa.
Methylnaltrexone
Methylnaltrexone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Methylphenidate
The risk or severity of hypertension can be increased when Methylphenidate is combined with Vilanterol.
Methyltestosterone
Methyltestosterone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Metolazone
The serum concentration of Metolazone can be increased when it is combined with Umeclidinium.
Metolazone
Vilanterol may decrease the antihypertensive activities of Metolazone.
Metreleptin
The metabolism of Vilanterol can be increased when combined with Metreleptin.
Metyrapone
Metyrapone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Metyrosine
Vilanterol may decrease the antihypertensive activities of Metyrosine.
Mexiletine
The metabolism of Umeclidinium can be decreased when combined with Mexiletine.
Midazolam
Midazolam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Midodrine
The risk or severity of Tachycardia can be increased when Midodrine is combined with Umeclidinium.
Midodrine
The risk or severity of hypertension can be increased when Midodrine is combined with Vilanterol.
Migalastat
Migalastat may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Milnacipran
The risk or severity of Tachycardia can be increased when Milnacipran is combined with Umeclidinium.
Milrinone
Milrinone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Mineral oil
The therapeutic efficacy of Mineral oil can be decreased when used in combination with Umeclidinium.
Minoxidil
Vilanterol may decrease the antihypertensive activities of Minoxidil.
Mirtazapine
The metabolism of Umeclidinium can be decreased when combined with Mirtazapine.
Monopotassium phosphate
The therapeutic efficacy of Monopotassium phosphate can be decreased when used in combination with Umeclidinium.
N-acetyltyrosine
Vilanterol may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabilone
The risk or severity of Tachycardia can be increased when Nabilone is combined with Vilanterol.
Nabumetone
The risk or severity of hypertension can be increased when Nabumetone is combined with Vilanterol.
Nadolol
The metabolism of Umeclidinium can be decreased when combined with Nadolol.
Naldemedine
Vilanterol may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalmefene
Nalmefene may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Naloxone
Naloxone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Naphazoline
The risk or severity of Tachycardia can be increased when Naphazoline is combined with Umeclidinium.
Naphazoline
The risk or severity of hypertension can be increased when Naphazoline is combined with Vilanterol.
Naproxen
The risk or severity of hypertension can be increased when Naproxen is combined with Vilanterol.
Naratriptan
The risk or severity of hypertension can be increased when Naratriptan is combined with Vilanterol.
Nateglinide
The metabolism of Umeclidinium can be decreased when combined with Nateglinide.
Nateglinide
Nateglinide may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Naxitamab
The risk or severity of hypertension can be increased when Vilanterol is combined with Naxitamab.
Nebivolol
The metabolism of Umeclidinium can be decreased when combined with Nebivolol.
Nedocromil
Nedocromil may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Nefazodone
The metabolism of Umeclidinium can be decreased when combined with Nefazodone.
Neostigmine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Neostigmine.
Nevirapine
The metabolism of Umeclidinium can be decreased when combined with Nevirapine.
Nicotine
The risk or severity of Tachycardia can be increased when Nicotine is combined with Umeclidinium.
Nicotine
The risk or severity of Tachycardia can be increased when Nicotine is combined with Vilanterol.
Nifedipine
The metabolism of Umeclidinium can be decreased when combined with Nifedipine.
Nilutamide
Nilutamide may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Nisoldipine
Vilanterol may decrease the antihypertensive activities of Nisoldipine.
Nitric Oxide
Nitric Oxide may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Nitrofurantoin
Nitrofurantoin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Nitroglycerin
Vilanterol may decrease the antihypertensive activities of Nitroglycerin.
Nitroprusside
Vilanterol may decrease the antihypertensive activities of Nitroprusside.
Nitrous oxide
The risk or severity of hypertension can be increased when Nitrous oxide is combined with Vilanterol.
Nizatidine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Nizatidine.
Norepinephrine
The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Umeclidinium.
Octinoxate
Vilanterol may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Olmesartan
Vilanterol may decrease the antihypertensive activities of Olmesartan.
Olodaterol
The risk or severity of Tachycardia can be increased when Umeclidinium is combined with Olodaterol.
Olsalazine
Olsalazine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Omaveloxolone
The serum concentration of Vilanterol can be decreased when it is combined with Omaveloxolone.
Ondansetron
The metabolism of Umeclidinium can be decreased when combined with Ondansetron.
Opium
Vilanterol may decrease the excretion rate of Opium which could result in a higher serum level.
Orciprenaline
The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Umeclidinium.
Oritavancin
The metabolism of Umeclidinium can be decreased when combined with Oritavancin.
Oseltamivir
Oseltamivir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Osilodrostat
The metabolism of Umeclidinium can be decreased when combined with Osilodrostat.
Ospemifene
The metabolism of Umeclidinium can be decreased when combined with Ospemifene.
Oxacillin
Oxacillin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Oxaprozin
The risk or severity of hypertension can be increased when Oxaprozin is combined with Vilanterol.
Oxazepam
Oxazepam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Oxybenzone
Oxybenzone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Oxybutynin
The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Vilanterol.
Oxymetazoline
The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Umeclidinium.
Oxymetazoline
The risk or severity of hypertension can be increased when Oxymetazoline is combined with Vilanterol.
Oxyquinoline
Vilanterol may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Palonosetron
The metabolism of Umeclidinium can be decreased when combined with Palonosetron.
Palonosetron
Palonosetron may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Pamidronic acid
Pamidronic acid may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Pancuronium
The risk or severity of Tachycardia can be increased when Pancuronium is combined with Vilanterol.
Pantoprazole
Pantoprazole may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Parecoxib
The risk or severity of hypertension can be increased when Parecoxib is combined with Vilanterol.
Paromomycin
Paromomycin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Paroxetine
The risk or severity of Tachycardia can be increased when Paroxetine is combined with Vilanterol.
Peginterferon alfa-2b
The metabolism of Umeclidinium can be decreased when combined with Peginterferon alfa-2b.
Pegvisomant
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Pegvisomant.
Pentamidine
The metabolism of Umeclidinium can be decreased when combined with Pentamidine.
Pentetic acid
Vilanterol may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital
The risk or severity of adverse effects can be increased when Pentobarbital is combined with Umeclidinium.
Pentoxifylline
Pentoxifylline may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Pergolide
The risk or severity of Tachycardia can be increased when Pergolide is combined with Umeclidinium.
Perindopril
Vilanterol may decrease the antihypertensive activities of Perindopril.
Permethrin
Permethrin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Phenazopyridine
Phenazopyridine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Phendimetrazine
The risk or severity of Tachycardia can be increased when Phendimetrazine is combined with Umeclidinium.
Phendimetrazine
The risk or severity of hypertension can be increased when Phendimetrazine is combined with Vilanterol.
Phenobarbital
The risk or severity of adverse effects can be increased when Phenobarbital is combined with Umeclidinium.
Phentermine
The risk or severity of Tachycardia can be increased when Phentermine is combined with Umeclidinium.
Phentermine
The risk or severity of hypertension can be increased when Phentermine is combined with Vilanterol.
Phenylephrine
The risk or severity of Tachycardia can be increased when Phenylephrine is combined with Umeclidinium.
Phenylephrine
The risk or severity of hypertension can be increased when Phenylephrine is combined with Vilanterol.
Phenytoin
The metabolism of Umeclidinium can be decreased when combined with Phenytoin.
Phosphoric acid
Vilanterol may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone
Phylloquinone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Physostigmine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Physostigmine.
Picosulfuric acid
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Umeclidinium.
Picosulfuric acid
Vilanterol may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Pindolol
The metabolism of Umeclidinium can be decreased when combined with Pindolol.
Piperacillin
Piperacillin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Pirfenidone
The metabolism of Umeclidinium can be decreased when combined with Pirfenidone.
Piroxicam
The risk or severity of hypertension can be increased when Piroxicam is combined with Vilanterol.
Pitolisant
The serum concentration of Umeclidinium can be increased when it is combined with Pitolisant.
Plantago seed
The therapeutic efficacy of Plantago seed can be decreased when used in combination with Umeclidinium.
Plecanatide
The therapeutic efficacy of Plecanatide can be decreased when used in combination with Umeclidinium.
Plerixafor
Plerixafor may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Polyethylene glycol
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Umeclidinium.
Polythiazide
The serum concentration of Polythiazide can be increased when it is combined with Umeclidinium.
Potassium
Potassium may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate
Vilanterol may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicarbonate
Vilanterol may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium bitartrate
The therapeutic efficacy of Potassium bitartrate can be decreased when used in combination with Umeclidinium.
Potassium cation
Potassium cation may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Potassium chloride
The risk or severity of gastrointestinal ulceration can be increased when Umeclidinium is combined with Potassium chloride.
Potassium chloride
Potassium chloride may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Potassium citrate
Potassium citrate may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Potassium nitrate
Vilanterol may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium sulfate
The therapeutic efficacy of Potassium sulfate can be decreased when used in combination with Umeclidinium.
Potassium sulfate
Vilanterol may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Pralidoxime
Pralidoxime may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Pramipexole
Pramipexole may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Prasugrel
Prasugrel may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Primidone
The risk or severity of adverse effects can be increased when Primidone is combined with Umeclidinium.
Probenecid
Probenecid may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Procaine
The risk or severity of adverse effects can be increased when Procaine is combined with Umeclidinium.
Procaine benzylpenicillin
Vilanterol may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Prochlorperazine
The metabolism of Umeclidinium can be decreased when combined with Prochlorperazine.
Progesterone
The metabolism of Umeclidinium can be decreased when combined with Progesterone.
Proguanil
The metabolism of Umeclidinium can be decreased when combined with Proguanil.
Propantheline
Propantheline may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Propranolol
The metabolism of Umeclidinium can be decreased when combined with Propranolol.
Propyphenazone
The risk or severity of hypertension can be increased when Vilanterol is combined with Propyphenazone.
Prucalopride
The therapeutic efficacy of Prucalopride can be decreased when used in combination with Umeclidinium.
Prucalopride
Prucalopride may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Pseudoephedrine
The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Umeclidinium.
Pseudoephedrine
The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Vilanterol.
Pyrantel
Vilanterol may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide
Pyrazinamide may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Pyridostigmine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Pyridostigmine.
Pyridoxine
Pyridoxine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Quinapril
Vilanterol may decrease the antihypertensive activities of Quinapril.
Rabeprazole
Rabeprazole may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Racepinephrine
The risk or severity of Tachycardia can be increased when Umeclidinium is combined with Racepinephrine.
Ramelteon
Ramelteon may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Ramipril
Vilanterol may decrease the antihypertensive activities of Ramipril.
Ranitidine
Ranitidine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Relugolix
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Relugolix.
Remifentanil
The risk or severity of hypertension can be increased when Remifentanil is combined with Vilanterol.
Reserpine
Vilanterol may decrease the antihypertensive activities of Reserpine.
Resorcinol
Vilanterol may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Ribavirin
Ribavirin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Riociguat
Vilanterol may decrease the antihypertensive activities of Riociguat.
Risperidone
The metabolism of Umeclidinium can be decreased when combined with Risperidone.
Rivaroxaban
Rivaroxaban may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Rivastigmine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Rivastigmine.
Rizatriptan
The risk or severity of hypertension can be increased when Rizatriptan is combined with Vilanterol.
Rocuronium
The risk or severity of Tachycardia can be increased when Rocuronium is combined with Vilanterol.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Vilanterol.
Ropivacaine
Ropivacaine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Rosiglitazone
Rosiglitazone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Rotigotine
The metabolism of Umeclidinium can be decreased when combined with Rotigotine.
Rotigotine
The risk or severity of hypertension can be increased when Rotigotine is combined with Vilanterol.
Sacubitril
Vilanterol may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Salicylamide
The risk or severity of hypertension can be increased when Salicylamide is combined with Vilanterol.
Salicylic acid
The risk or severity of hypertension can be increased when Salicylic acid is combined with Vilanterol.
Salmeterol
The risk or severity of Tachycardia can be increased when Salmeterol is combined with Umeclidinium.
Salmon calcitonin
Salmon calcitonin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Salsalate
The risk or severity of hypertension can be increased when Salsalate is combined with Vilanterol.
Saxagliptin
Saxagliptin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Scopolamine
The risk or severity of Tachycardia can be increased when Scopolamine is combined with Vilanterol.
Secobarbital
The risk or severity of adverse effects can be increased when Secobarbital is combined with Umeclidinium.
Secobarbital
Secobarbital may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Selegiline
The metabolism of Umeclidinium can be decreased when combined with Selegiline.
Selenious acid
Vilanterol may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium
Vilanterol may decrease the excretion rate of Selenium which could result in a higher serum level.
Selexipag
Vilanterol may decrease the antihypertensive activities of Selexipag.
Senna leaf
The therapeutic efficacy of Senna leaf can be decreased when used in combination with Umeclidinium.
Sennosides
The therapeutic efficacy of Sennosides can be decreased when used in combination with Umeclidinium.
Serdexmethylphenidate
The risk or severity of hypertension can be increased when Vilanterol is combined with Serdexmethylphenidate.
Sertraline
The metabolism of Umeclidinium can be decreased when combined with Sertraline.
Sitagliptin
Sitagliptin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Sodium acetate
Vilanterol may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium ascorbate
The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Umeclidinium.
Sodium cation
The therapeutic efficacy of Sodium cation can be decreased when used in combination with Umeclidinium.
Sodium fluoride
Vilanterol may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium fluorophosphate
The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Umeclidinium.
Sodium phosphate, dibasic
The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Umeclidinium.
Sodium phosphate, dibasic, unspecified form
The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Umeclidinium.
Sodium phosphate, monobasic
The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Umeclidinium.
Sodium phosphate, monobasic, unspecified form
The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Umeclidinium.
Sodium sulfate
The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Umeclidinium.
Sodium sulfate
Vilanterol may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sofosbuvir
Sofosbuvir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Somatrogon
The metabolism of Vilanterol can be increased when combined with Somatrogon.
Sorbitol
The therapeutic efficacy of Sorbitol can be decreased when used in combination with Umeclidinium.
Sorbitol
Sorbitol may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Sotatercept
Vilanterol may decrease the antihypertensive activities of Sotatercept.
Stiripentol
The excretion of Umeclidinium can be decreased when combined with Stiripentol.
Sucralfate
Sucralfate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Sufentanil
The risk or severity of hypertension can be increased when Sufentanil is combined with Vilanterol.
Sulbactam
Vilanterol may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine
Sulfadiazine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Sulfate ion
The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Umeclidinium.
Sulindac
The risk or severity of hypertension can be increased when Sulindac is combined with Vilanterol.
Sumatriptan
The risk or severity of hypertension can be increased when Sumatriptan is combined with Vilanterol.
Synthetic Conjugated Estrogens, A
Vilanterol may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
Synthetic Conjugated Estrogens, B
Vilanterol may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tadalafil
Vilanterol may decrease the antihypertensive activities of Tadalafil.
Tafenoquine
The metabolism of Umeclidinium can be decreased when combined with Tafenoquine.
Tamsulosin
The metabolism of Umeclidinium can be decreased when combined with Tamsulosin.
Tapentadol
The risk or severity of urinary retention and constipation can be increased when Umeclidinium is combined with Tapentadol.
Tasimelteon
Tasimelteon may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Technetium Tc-99m exametazime
Vilanterol may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc-99m pyrophosphate
Vilanterol may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Teduglutide
Teduglutide may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Telmisartan
Vilanterol may decrease the antihypertensive activities of Telmisartan.
Temazepam
Temazepam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tenofovir disoproxil
Tenofovir disoproxil may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Terbutaline
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Terbutaline.
Testosterone
Testosterone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Testosterone cypionate
Vilanterol may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone enanthate
Vilanterol may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone propionate
Testosterone propionate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tetrabenazine
The metabolism of Umeclidinium can be decreased when combined with Tetrabenazine.
Tetracycline
Tetracycline may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tetradecyl hydrogen sulfate (ester)
Vilanterol may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Tetryzoline
The risk or severity of Tachycardia can be increased when Tetryzoline is combined with Umeclidinium.
Tetryzoline
The risk or severity of hypertension can be increased when Tetryzoline is combined with Vilanterol.
Theophylline
The risk or severity of hypokalemia can be increased when Theophylline is combined with Vilanterol.
Thiotepa
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Thiotepa.
Thonzylamine
The risk or severity of Tachycardia can be increased when Vilanterol is combined with Thonzylamine.
Ticlopidine
Ticlopidine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Timolol
The metabolism of Umeclidinium can be decreased when combined with Timolol.
Tinidazole
Tinidazole may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tiopronin
Tiopronin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tiotropium
Tiotropium may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tirofiban
Tirofiban may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tizanidine
The risk or severity of Tachycardia can be increased when Tizanidine is combined with Umeclidinium.
Tocopherol
Vilanterol may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tocopherylquinone
Vilanterol may decrease the antihypertensive activities of Tocopherylquinone.
Tolazamide
Tolazamide may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tolcapone
Tolcapone may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tolmetin
The risk or severity of hypertension can be increased when Tolmetin is combined with Vilanterol.
Tolvaptan
Tolvaptan may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Topiramate
Topiramate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tramadol
Tramadol may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Trametinib
Trametinib may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Trandolapril
Vilanterol may decrease the antihypertensive activities of Trandolapril.
Trazodone
The metabolism of Umeclidinium can be decreased when combined with Trazodone.
Triamterene
Triamterene may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Triazolam
Triazolam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Triethylenetetramine
Triethylenetetramine may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Trihexyphenidyl
The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Vilanterol.
Trimethoprim
Trimethoprim may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Trimetrexate
Trimetrexate may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Tropicamide
The risk or severity of adverse effects can be increased when Tropicamide is combined with Umeclidinium.
Trospium
The risk or severity of Tachycardia can be increased when Trospium is combined with Vilanterol.
Vaborbactam
Vilanterol may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Vadadustat
The serum concentration of Vilanterol can be increased when it is combined with Vadadustat.
Valaciclovir
Valaciclovir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Valbenazine
The metabolism of Valbenazine can be decreased when combined with Umeclidinium.
Valbenazine
Vilanterol may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib
The risk or severity of hypertension can be increased when Valdecoxib is combined with Vilanterol.
Valganciclovir
Valganciclovir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Valsartan
Vilanterol may decrease the antihypertensive activities of Valsartan.
Varenicline
Varenicline may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Vecuronium
The risk or severity of adverse effects can be increased when Vecuronium is combined with Umeclidinium.
Venlafaxine
The metabolism of Umeclidinium can be decreased when combined with Venlafaxine.
Vibrio cholerae CVD 103-HgR strain live antigen
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Vilanterol.
Vilazodone
The risk or severity of hypertension can be increased when Vilazodone is combined with Vilanterol.
Viloxazine
The metabolism of Umeclidinium can be decreased when combined with Viloxazine.
Viloxazine
The metabolism of Vilanterol can be decreased when combined with Viloxazine.
Vinorelbine
The metabolism of Umeclidinium can be decreased when combined with Vinorelbine.
Vortioxetine
The metabolism of Umeclidinium can be decreased when combined with Vortioxetine.
Vortioxetine
The risk or severity of hypertension can be increased when Vortioxetine is combined with Vilanterol.
Xanomeline
The metabolism of Xanomeline can be decreased when combined with Umeclidinium.
Xylometazoline
The risk or severity of Tachycardia can be increased when Xylometazoline is combined with Umeclidinium.
Xylometazoline
The risk or severity of hypertension can be increased when Xylometazoline is combined with Vilanterol.
Zaleplon
Zaleplon may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Zanamivir
Zanamivir may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Zolmitriptan
The risk or severity of hypertension can be increased when Zolmitriptan is combined with Vilanterol.
Zolpidem
The metabolism of Umeclidinium can be decreased when combined with Zolpidem.